| Patent Use Code |
Code meaning |
| U |
Patent Use Code (See Individual References) |
| U-1 |
Prevention Of Pregnancy |
| U-10 |
Diagnostic Method For Distinguishing Between Hypothalmic Malfunctions Or Lesions In Humans |
| U-100 |
Method Of Treating Ocular Inflammation |
| U-1000 |
Adjunctive Therapy To Diet In Patients With Hyperlipidemias |
| U-1001 |
Method For Delivering Drug To Lung Of Mammal, Comprising Administering Drug Product By Inhalation. Treating A Mammal Having A Condition Capable Of Treatment By Inhalation, Comprising Administering To The Lung The Drug Product By Inhalation |
| U-1002 |
Method Of Treating Inflammatory Conditions |
| U-1003 |
A Method Of Myocardial Perfusion Imaging And Increasing Coronary Blood Flow |
| U-1004 |
Treatment Of Patients With Relapsed Or Refractory Peripheral T-Cell Lymphoma |
| U-1005 |
Method Of Treating A Staphylococcal Infection |
| U-1006 |
New Combination Product For The Early Treatment Of Recurrent Herpes Labialis (Cold Sores) To Reduce The Likelihood Of Ulcerative Cold Sores And To Shorten The Lesion Healing Time In Adults And Adolescents (12 Years Of Age And Older) |
| U-1007 |
Method Of Treating Gout Flares |
| U-1008 |
Application Of Antiseptic With Moisturizers For Surgical And Healthcare Personnel Skin Disinfection |
| U-1009 |
Method For Administration Of Testosterone |
| U-101 |
Adjunct To Conventional Ct Or Mri Imaging In The Localization Of Stroke In Patients In Whom Stroke Has Already Been Diagnosed |
| U-1010 |
To Reduce Blood Phenylalanine Levels In Patients With Hyperphenylalaninemia Due To Tetra Hydrobiopterin Responsive Phenylketonuria. Kuvan Should Be Taken Orally With Food To Increase Absorption |
| U-1011 |
Use Of Granisetron Transdermal System To Treat/Prevent Chemotherapy Induced Nausea And Vomiting |
| U-1012 |
Method For Treating Insomnia While Reducing The Risk Of An Adverse Drug Interaction |
| U-1013 |
Method Of Using Ribavirin In Combination With Pegylated Interferon Alpha-2b To Treat Patients With Chronic Hepatitis C |
| U-1014 |
Method Of Using Ribavirin In Combination With Interferon Alpha-2b(Pegylated And Nonpegylated) To Treat Patients With Chronic Hepatitis C |
| U-1015 |
Treatment Of Patients With Relapsed Or Refractory Peripheral T-Cell Lymphoma |
| U-1016 |
In Combination With Other Antiretroviral Agents For The Treatment Of Hiv-1 Infection In Treatment-Experienced Adult Patients, Who Have Evidence Of Viral Replication And Hiv-1 Strains Resistant To An Nnrti And Other Antiretroviral Agents |
| U-1017 |
A Method Of Treating Nasal And Non-Nasal Symptoms Of Seasonal Allergic Rhinitis |
| U-1018 |
Treatment Of Pulmonary Hypertension By Inhalation |
| U-1019 |
Treatment Of Pulmonary Hypertension |
| U-102 |
Method Of Hormonally Treating Menopausal Or Post-Menopausal Disorders In Women |
| U-1020 |
Method Of Using Colchicine For The Prophylaxis Of Gout Flares |
| U-1021 |
Short-Term Treatment (4-8 Weeks) Of Active Benign Gastric Ulcer |
| U-1022 |
For The Preparation Of Skin Prior To Surgery; Helps Reduce Bacteria That Can Potentially Cause Skin Infection |
| U-1023 |
Treatment Of Atrophic Vaginitis Due To Menopause |
| U-1024 |
Reduction Of Elevated Intraocular Pressure In Patients With Glaucoma Or Ocular Hypertension Who Require Adjunctive Or Replacement Therapy Due To Inadequately Controlled Iop |
| U-1025 |
Treating Frequent Heartburn |
| U-1026 |
A Method Of Treating Human Suffering From Or Susceptible To Psychosis. |
| U-1027 |
Reduction Of Elevated Plasma Sterol And/Or Stanol Levels In A Mammal |
| U-1028 |
A Method Of Distributing Sodium Oxybate Under Control Of A Central Pharmacy |
| U-1029 |
Method For Treating Acute Elevations Of Blood Pressure In Human Subject In Need Thereof |
| U-103 |
Treatment Of Ocular Hypertension |
| U-1030 |
Improvement Of Walking In Patients With Multiple Sclerosis (Ms) |
| U-1031 |
Improve Respiratory Symptoms In Cystic Fibrosis In Patients With Pseudomonas Aeruginosa |
| U-1032 |
Use Of Rosuvastatin Calcium For The Primary Prevention Of Cardiovascular Disease In Individuals Without Clinically Evident Coronary Heart Disease But With Increased Risk Factors |
| U-1033 |
Topical Treatment Of Acne Vulgaris |
| U-1034 |
Treatment Of Attention Deficit Hyperactivity Disorder (Adhd) In Adults |
| U-1035 |
Nonsteroidal Anti-Inflammatory Drug Indicated For Relief Of Mild To Moderate Acute Pain |
| U-1036 |
Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-4 Inhibitor In Combination With Insulin |
| U-1037 |
Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-Iv Inhibitor In Combination With A Ppar-Gamma Agonist |
| U-1038 |
Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-4 Inhibitor In Combination With Metformin And A Ppar-Gamma Agonist |
| U-1039 |
Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-4 Inhibitor In Combination With Metformin |
| U-104 |
Treatment Of Aqueous Humor Formation And Intraocular Pressure |
| U-1040 |
Inhibition Of Thrombin In A Patient |
| U-1041 |
Treatment Of Disorders Responsive To Growth Hormone |
| U-1042 |
Method For Stimulating Coronary Vasodilation For Purposes Of Imaging The Heart |
| U-1043 |
Management Of Moderate To Severe Pain |
| U-1044 |
Topical Treatment Of Scalp Psoriasis |
| U-1045 |
Maintenance Treatment In Patients With Locally Advanced Or Metastatic Nsclc Who Have Not Progressed On 1st-Line Treatment Wth Platinum-Based Chemotherapy |
| U-1046 |
Maintenance Treatment Of Patients With Locally Advanced Or Metastatic Nsclc Whose Disease Has Not Progressed After Four Cycles Platinum-Based Chemotherapy |
| U-1047 |
Treatment Of Biopsy-Confirmed, Primary Superficial Basal Cell Carcinoma (Sbcc) |
| U-1048 |
Works Through The Induction Of Interferon And Other Cytokines |
| U-1049 |
Prophylaxis Of Organ Rejection In Adult Patients At Low-Moderate Immunologic Risk Receiving A Renal Transplant |
| U-105 |
Emesis |
| U-1050 |
Use Of Metaxalone For Treatment Of Musculskeletal Conditions |
| U-1051 |
Treatment Of Oropharyngeal Candidiasis |
| U-1052 |
Relief Of Signs And Symptoms Of Arthritis And Risk-Reduction Of Nsaid-Associated Gastric Ulcer |
| U-1053 |
Risk-Reduction Of Nsaid-Associated Gastric Ulcer |
| U-1054 |
Onychomycosis Of The Toenail Caused By Tricophyton Rubrum Or Trichophyton Mentagrophytes, Once Daily Use For 12 Consecutive Weeks |
| U-1055 |
An Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus Who Are Already Treated With A Thiazolidinedione (Tzd) And Metformin Or Who Have Inadequate Glycemic Control On A Tzd Or Metformin Alone |
| U-1056 |
Treatment Of Pain Using A Nasal Spray Of Ketorolac Tromethamine |
| U-1057 |
Treatment Of Inflammation And Pain Using A Nasal Spray Of Ketorolac Tromethamine |
| U-1058 |
Use Of Thalidomide In Combination With Dexamethasone For The Treatment Of Patients With Newly Diagnosed Multiple Myeloma |
| U-1059 |
Adjunctive Therapy To Diet To Patients With Hypertriglyceridemia |
| U-106 |
Treatment Of Epilepsy |
| U-1060 |
Adjunctive Therapy To Diet In Patients With Elevated Cholesterol And/Or Lipid Levels |
| U-1061 |
Adjunctive Therapy To Diet In Patients With Mixed Dyslipidemia |
| U-1062 |
Administration Of Approved Product For Treatment Of Alzheimer's Disease |
| U-1063 |
Treatment Of Only Inflammatory Lesions (Papules And Pustules) Of Rosacea |
| U-1064 |
Treatment Of Bipolar Disorder And Schizophrenia |
| U-1065 |
Method Of Treating Androgen Responsive Or Medicated Condition In A Mammal By Administering A Safe & Effective Amount Of Dutasteride Or A Pharmaceutically Acceptable Solvate Thereof.. Conditions Include Benign Prostatic Hypertrophy |
| U-1066 |
Method Of Treating An Androgen Response Or Mediated Disease In A Mammal By Admininstering An Effective Androgen Responsive Or Medicated Disease Amount Of Dutasteride..Conditions Include Benign Prostatic Hyperplasia |
| U-1067 |
Treatment Of Cancer |
| U-1068 |
Treatment Of Asthma |
| U-1069 |
A Method Of Treating A Patient With A Prescription Drug Using An Exclusive Computer Database In A Computer System For Distribution |
| U-107 |
Treatment Of Hypertension And Angina Pectoris |
| U-1070 |
A Method To Control Abuse Of A Sensitive Drug By Controlling With A Computer Processor The Distribution Of The Sensitive Drug Via An Exclusivity Central Pharmacy That Maintains A Central Database |
| U-1071 |
Method Of Treating Bladder Dsyfunction With Once A Day Trospium Salt Formulation |
| U-1072 |
The Management Of Moderate To Severe Chronic Pain In Patients Requiring A Continuous, Around-The-Clock Opioid Analgesic For An Extended Period Of Time |
| U-1073 |
Use For The Treatment Of Asthma And Copd |
| U-1074 |
Use Of Exenatide May Result In Reduction In Body Weight |
| U-1075 |
Use For The Treatment Of Asthma |
| U-1076 |
Reduce Chronic Severe Drooling (I.E., Sialorrhea) In Patients With Neurologic Conditions Associated With Problem Drooling |
| U-1077 |
Pretreatment Of Patients With Vitamin B12 And Folic Acid Prior To Pemetrexed Disodium Administraion |
| U-1078 |
Treatment Of Acne |
| U-1079 |
Revlimid (Lenalidomide) Is Indicated For The Treatment Of Patients With Transfusion-Dependent Anemia In Myelodysplastic Syndromes (Mds) |
| U-108 |
Short-Term Treatment Of Active Duodenal Ulcer, Gastroesophageal Reflux Disease (Gerd), Severe Erosive Esophagitis, Poorly Responsive Symptomatic Gerd And Pathologial Hypersecretory Conditions And Maintenance Healing Of Erosive Esophagitis |
| U-1080 |
Method To Treat Pulmonary Hypertension By Administering Ambrisentan To A Patient |
| U-1081 |
Lumigan Is A Prostaglandin Analog Indicated For The Reduction Of Elevated Intraocular Pressure In Patients With Open Angle Glaucoma Or Ocular Hypertension |
| U-1082 |
Use Of A Combination Of Tobramycin And Dexamethasone To Treat Ocular Inflammation Where An Infection Or Risk Of Infection Exists |
| U-1083 |
Acute Treatment Of Migraine Attacks, With Or Without Aura, And The Treatment Of Cluster Headache Episodes |
| U-1084 |
Relief Of The Inflammatory And Pruritic Manifestations Of Corticosteroid Responsive Dermatoses In Patients 12 Years Of Age Or Older |
| U-1085 |
Method For Treating Irritable Bowel Syndrome And Method For Treating Abdominal Discomfort Associated With Irritable Bowel Syndrome |
| U-1086 |
Treatment Of Autoimmune Disease |
| U-1087 |
Detection Of Non-Muscle Invasive Papillary Cancer Of The Bladder By Photodynamic Cystoscopy |
| U-1088 |
Relief Of Muscle Spasm |
| U-1089 |
Inhibition Of Thrombin |
| U-109 |
Adjunct Diet In The Tx Of Elevated Total Cholesterol And Ldl-C Levels In Pts W/Primary Hypercholesterolemia Whose Response To Dietary Restriction Of Sat Fat And Cholesterol And Other Nonpharmacological Measures Has Not Been Adequate |
| U-1090 |
Lo Loestrin Fe Is Indicated For The Prevention Of Pregnancy In Women Who Elect To Use Oral Contraceptives As A Methof Of Contraception |
| U-1091 |
Assessment Of Bronchial Hyperresponsiveness In Patients 6 Years Of Age Or Older Who Do Not Have Clinically Apparent Asthma |
| U-1092 |
Treatment Of Breast Cancer |
| U-1093 |
Treatment Of Pseudobulbar Affect |
| U-1094 |
Management Of Chronic Musculoskeletal Pain |
| U-1095 |
Method Of Treating Ocular Inflammation |
| U-1096 |
Treatment Of Patients With Metastatic Breast Cancer |
| U-1097 |
Adjunct To Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus When Treatment With Both Saxagliptin And Metformin Is Appropriate |
| U-1098 |
Method Of Treating Hyperparathyroidism; Method Of Treating Hypercalcemia |
| U-1099 |
Treatment Of Pain, Including Neuropathic Pain Associated With Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, And Fibromyalgia |
| U-11 |
Treatment Or Prophylaxis Of Cardiac Disorders |
| U-110 |
Use As A Retrievable Perssary |
| U-1100 |
Reduction Of Excess Abdominal Fat In Hiv-Infected Patients With Lipodystrophy |
| U-1101 |
Method Of Treating Excessive Daytime Sleepiness In Patients With Narcolepsy |
| U-1102 |
Method Of Treating Cataplexy In Patients With Narcolepsy |
| U-1103 |
Testosterone Replacement Therapy In Males For Conditions Associated With A Deficiency Or Absence Of Endogenous Testosterone |
| U-1104 |
Use Of Tramadol For The Management Of Moderate To Moderately Severe Chronic Pain |
| U-1105 |
Topical Treatment Of Head Lice Infestation In Patients Four (4) Years Of Age And Older |
| U-1106 |
Treating Hypertriglyceridemias With Reduction Of Food Effect |
| U-1107 |
Treating Hypercholesterolemias With Reduction Of Food Effect |
| U-1108 |
Treating Type 2 Diabetes Mellitus With Exenatide By Stimulating Insulin Release |
| U-1109 |
Treatment Of Cutaneous Manifestations Of Erythema Nodosum Leprosum (Enl) In Connection With A Special Program Approved By Fda Called "System For Thalidomide Education And Prescribing Safety" (S.T.E.P.S.) |
| U-111 |
Diabetes |
| U-1110 |
Method Of Treating A Patient With A Prescription Drug Using A Computer Database In A Computer System For Distribution |
| U-1111 |
Nonsteroidal Anti-Inflammatory Drug Indicated For Relief Of Mild To Moderate Acute Pain |
| U-1112 |
Method Of Mr Imaging Of A Mammal |
| U-1113 |
Treatment And Prophylaxis Of Influenza |
| U-1114 |
Treatment With Gabapentin, Including Treatment Of Neuropathic Pain, Including Neuropathic Pain Associated With Postherpetic Neuralgia |
| U-1115 |
Treatment To Reduce The Risk Of Copd Exacerbations In Patients With Severe Copd Associated With Chronic Bronchitis And A History Of Exacerbations |
| U-1116 |
Method Of Administering Colchicine To Familial Mediterranean Fever Patients |
| U-1117 |
Treatment Of Breast Cancer |
| U-1118 |
Use For The Treatment Of Chronic Obstructive Pulmonary Disease (Copd), Including Chronic Bronchitis And Emphysema |
| U-1119 |
Contrast Agent For Magnetic Resonance Imaging |
| U-112 |
Contraception |
| U-1120 |
To Reduce Gastrointestinal Side Effects Administer With A Meal; As Starting Dose Administer Once Daily With Evening Meal |
| U-1121 |
Method Of Treating Travelers' Diarrhea |
| U-1122 |
Treatment Of Secondarily Infected Traumatic Skin Lesions Due To S. Aureus And S. Pyogenes |
| U-1123 |
Treatment Of Alcohol Dependence |
| U-1124 |
Prevention Of Relapse To Opioid Dependence, Following Opioid Detoxification |
| U-1125 |
Method For The Detection Of Neuroendocrine Tumors |
| U-1126 |
Use In Combination With Prednisone For The Treatment Of Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel |
| U-1127 |
Treatment Of Patent Ductus Arteriosus |
| U-1128 |
Treatment Of Chronic Hepatitis C (Chc) Genotype 1 Infection In Combination With Peginterferon Alfa And Ribavirin In Adult Patients (>=18 Years Of Age) With Compensated Liver Disease |
| U-1129 |
Treatment Of Hypercholesterolemia By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibitin Agent Such As Aspirin |
| U-113 |
Method Of Conducting Radiological Examination Of A Patient By Administering To Said Patient A Radiopaque Amount Of Iopromide |
| U-1130 |
Secondary Prevention Of Cardiovascular Events By Dosing Once Per Day In The Evening Or A Night With Pretreatment With A Flush Inhibiting Agent Such As Aspirin |
| U-1131 |
Treatment Of Hypertriglyderidemia By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibitin Agent Such As Aspirin |
| U-1132 |
Treatment Of Hypercholesterolemia By Dosing Once Per Day In The Evening Or At Night |
| U-1133 |
Secondary Prevention Of Cardiovascular Events By Dosing Once Per Day In The Evening Or At Night |
| U-1134 |
Treatment Of Hypertriglyceridemia By Dosing Once Per Day In The Evening Or At Night |
| U-1135 |
Treatment Of Hypercholesterolemia By Dosing Once Per Day In The Evening Or At Night, Through Reduction Of Ldl-C, Tc, Tg, Lp(A) And Increase Of Hdl-C |
| U-1136 |
Secondary Prevention Of Cardiovascular Events By Dosing Once Per Day In The Evening Or At Night, Through Reduction Of Ldl-C, Tc, Tg, Lp(A), And Increase Of Hdl-C |
| U-1137 |
Treatment Of Hypertriglyceridemia By Dosing Once Per Day In The Evening Or At Night, Through Reduction Of Ldl-C, Tc, Tg, Lp(A), And Increase Of Hdl-C |
| U-1138 |
Treatment Of Primary And Mixed Dyslipidemia By Dosing Once Per Day In The Evening Or At Night |
| U-1139 |
Reduction In Risk Of Recurrent Nonfatal Myocardial Infarction By Dosing Once Per Day In The Evening Or At Night |
| U-114 |
Use For Inhibiting Bone Resorption |
| U-1140 |
Reduction In Elevated Tc And Ldl-C By Dosing Once Per Day In The Evening Or At Night |
| U-1141 |
Reduction In Tg By Dosing Once Per Day In The Evening Or At Night |
| U-1142 |
Treatment Of Primary And Mixed Dyslipidemia By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibiting Agent Such As Aspirin |
| U-1143 |
Reduction In Risk Of Recurrent Nonfatal Myocardial Infarction By Dosing Once Per Day In The Evening Or A T Night, With Pretreatment With A Flush Inhibitin Agent Such As Aspirin |
| U-1144 |
Reduction In Elevated Tc And Ldl-C By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibitin Agent Such As Aspirin |
| U-1145 |
Reduction In Tg By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibiting Agent Such As Aspirin |
| U-1146 |
Reduction In Tg With Reduced Flushing By Dosing Once Per Day In The Evening Or At Night |
| U-1147 |
Treatment Of Primary And Mixed Dyslipidemia By Dosing Once Per Day In The Evening Or At Night, Through Reduction Of Ldl-C, Tc, Tg, Lp(A), And Increase Of Hdl-C |
| U-1148 |
Reduction In Risk Of Recurrent Nonfatal Myocardial Infarction By Dosing Once Per Day In The Evening Or At Night, Through Reductino Of Ldl-C, Tc, Tg, Lp(A), And Increase Of Hdl-C |
| U-1149 |
Treatment Of Hypertriglyceridemia By Dosing Once Per Day In The Evening Or At Night, With Pretreatment With A Flush Inhibiting Agent Such As Aspirin |
| U-115 |
Use Of Vasodilators To Effect And Enhance An Erection (And Thus Treat Erectile Dysfunction), By Injection Into The Penis |
| U-1150 |
Tretment Of Hypercholesterolemia By Dosing Once Per Day In The Evening Or At Night, Through Reduction In Total-C, Ldl-C, Tg, Lp(A), And Increase Of Hdl-C |
| U-1151 |
Treatment Of Hypertriglycderidemia By Dosing Once Per Day In The Evening Or At Night, Through Reduction In Total-C, Ldl-C, Lp(A), And Increase Of Hdl-C |
| U-1152 |
Cyanocobalamin Administration Through Nasal Infusion |
| U-1153 |
In Combination With Other Antiretroviral Agents, Is Indicated For The Treatment Of Human Immunodeficiency Virus Type 1 (Hiv-1) Infection In Antiretroviral Treatment-Naive Adult Patients, As Set Forth In The Labeling, Including I&U Section |
| U-1154 |
Treatment Of Protein Kinase Related Disorders, Such As Gastrointestinal Stromal Tumors, Renal Cell Carcinoma And Advanced Pancreatic Neuroendocrine Tumors, With Sunitinib |
| U-1155 |
Use Of Thalidomide In Treatment Of Cutaneous Manifestations Of Erythema Nodosum Leprosum (Enl) |
| U-1156 |
To Reduce Blood Phenylalanine (Phe) Levels In Patinets With Hyperphenylalaninemia (Hpa) |
| U-1157 |
Relief Of Symptoms Associated With Respiratory Allergies In Adults And Children 2 Years Of Age And Older And For The Relief Of Symptoms Associated With Hives (Urticaria) In Adults And Children 6 Years Of Age And Older |
| U-1158 |
Relief Of Symptoms Associated With Respiratory Allergies And For The Relief Of Symptoms Associated With Hives (Urticaria) In Adults And Children 6 Years Of Age And Older |
| U-1159 |
Relief Of Symptoms Associated With Respiratory Allergies, Swelling Of The Nasal Passages And Sinus Congestion And Pressure In Adults And Children 12 Years Of Age And Older |
| U-116 |
Method Of Myocardial Imaging |
| U-1160 |
Relief Of Symptoms Associated With Respiratory Allergies And For The Relief Of Symptoms Associated With Hives (Urticaria) In Adults And Children 6 Years Of Age And Older And 12 Years Of Age And Older |
| U-1161 |
For The Treatment And Prophylaxis Of Gout Flares & The Treatment Of Familial Mediterranean Fever |
| U-1162 |
Treatment Of Seborrheic Dermatitis Of The Scalp |
| U-1163 |
Method Of Treating Thrombosis |
| U-1164 |
Method Of Treating An Argatroban Treatable Condition |
| U-1165 |
Use For The Treatment Of Multiple Myeloma |
| U-1166 |
A Method For Treatment Of Gout Flares During Prophylaxis |
| U-1167 |
Prophylaxis Of Deep Vein Thrombosis (Dvt) |
| U-1168 |
The Long Term, Once-Daily Maintenance Brochodilator Treatment Of Airflow Obstruction In Patients With Chronic Obstructive Pulmonary Disease (Copd), Including Chronic Bronchitis And/Or Emphysema |
| U-1169 |
Management Of Breakthrough Pain In Cancer Patients 18 Years Of Age And Older Who Are Receiving And Tolerant To Opioid Therapy For Their Underlying Persistent Cancer Pain |
| U-117 |
Treatment Of Ocular Allergic Response In Human Eyes |
| U-1170 |
Treatment Of Hiv-1 Infection In Pediatric Patients 12 Years Of Age And Older |
| U-1171 |
Reduction Of The Rate Of Thrombotic Events In Patients With Acute Coronary Syndrome |
| U-1172 |
To Reduce Elevated Total-C, Apo B, And Non-Hdl-C In Patients Wiht Primary Hyperlipidemia By Administration Of Ezetimibe In Combination With A Statin |
| U-1173 |
To Reduce Elevated Total-C, Ldl-C, Apo B And Non-Hdl-C In Patients With Primary Hyperlipidemia By Administration Of Ezetimibe Alone Or In Combination With A Statin Or With Fenofibrate |
| U-1174 |
Administration Of Remodulin Diluted For Intravenous Infusion With Sterile Water For Injection, 0.9% Sodium Chloride Injection, Or Flolan Steriile Diluent For Injection Prior To Administration |
| U-1175 |
Reduction Of Cardiac Tissue Damage Associated With Myocardial Infarction |
| U-1176 |
Treatment Or Prevention Of Stroke |
| U-1177 |
Reduction Of Cardiac Tissue Damage Associated With Myocardial Infarction |
| U-1178 |
Relief Of Moderate To Severe Chronic Pain |
| U-1179 |
Treatment Of A Cancer Mediated By An Anaplastic Lymphoma Kinase (Alk) |
| U-118 |
Method Of Lowering Blood Sugar Level |
| U-1180 |
Treatment Of The Following Infections: Complicated Skin And Skin Structure Infections And Staphylococcus Aureus Bloodstream Infections (Bacteremia) Including Those With Right-Sided Infective Endocarditis |
| U-1181 |
A Method Of Treating Or Preventing Ocular Pain In A Patient |
| U-1182 |
Treatment Of Cyclic Heavy Menstrual Bleeding |
| U-1183 |
A Method For Administering Follicle Stimulating Hormone (Fsh) For Ovarian Follicle Or Testicular Stimulation In The Human |
| U-1184 |
Treatment Of Erectile Dysfunction And The Signs And Symptoms Of Benign Prostatic Hyperplasia |
| U-1185 |
Treatment Of Opioid-Induced Constipation |
| U-1186 |
Administration Of An Inhalable Powder Comprising Tiotropium Via Device |
| U-1187 |
Treatment Of Pathological State By Antagonizing Bradykinin Receptor Including Treatment Of Acute Attacks Of Hereditary Angioedema (Hae) |
| U-1188 |
Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate |
| U-1189 |
Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate, In Combination With Metformin |
| U-119 |
Treatment Of Nasal Hypersecretion |
| U-1190 |
Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate, In Combination With Insulin |
| U-1191 |
Method Of Tx Type 2 Dm In Pts For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate, In Combo With An Agent Acting On An Atp-Dependent Channel In Beta Cells Such As A Sulfyonylurea(Incl Glipizide, Glimepiriide & Glyburide) |
| U-1192 |
Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate, In Combination With A Sulfonylurea (Such As Glipizide, Glimepiride And Glyburide) |
| U-1193 |
Method Of Treating Type 2 Diabetes Melitus In Patients For Whom Treatment With Both Sitagliptin And Simvastatin Is Appropriate, In Combination With A Ppar-Gamma Agonist (Such As Pioglitazone And Rosiglitazone) |
| U-1194 |
Method For Treating Insomnia |
| U-1195 |
Prevention And Treatment Of Secondary Hyperparathyroidism Associated With Chronic Kidney Disease (Ckd) Stage 5, Which May Result In Renal Osteodystrophy, While Avoiding Hyperphosphatemia |
| U-1196 |
Relief Of Signs And Symptoms Of Rheumatoid Arthritis And Osteoarthritis And To Decrease Risk Of Developing Upper Gastrointestinal Ulcers In Patients Who Are Taking Ibuprofen For Those Indications |
| U-1197 |
Method Of Treatment Of Children With Central Precocious Puberty |
| U-1198 |
Rectiv Is A Nitrate Vasodilator Indicated For The Treatment Of Moderate To Severe Pain Associated With Chronic Anal Fissure |
| U-1199 |
Treatment And Prevention Of Postmenopausal Or Glucocorticoid-Induced Osteoporosis And Treatment To Increase Bone Mass In Men With Osteoporosis |
| U-12 |
Method Of Treating [A] Human Suffering From Depression |
| U-120 |
Controlling Or Preventing Post-Operative Intraocular Pressure Rises Associated With Ophthalmic Laser Surgical Procedures |
| U-1200 |
Reducing The Risk Of Stroke And Systemic Embolism |
| U-1201 |
For The Treatment Of Intermediate Or High-Risk Myelofibrosis |
| U-1202 |
Method For Relieving Or Treating Constipation In A Patient With Irritable Bowel Syndrome |
| U-1203 |
Method For Relieving Or Treating Constipation In A Human Constipated Patient |
| U-1204 |
Treatment Of Uveitis |
| U-1205 |
Treatment Of Macular Edema |
| U-1206 |
Delivering An Ocular Implant As Described In The Dosage And Administration Section Of The Approved Labeling Of Ozurdex |
| U-1207 |
Infant Use Aged 1 Month To Less Than One Year, Gerd And Erosive Esophagitis |
| U-1208 |
Treatment Of Hypotrichosis Of The Eyelashes By Increasing Their Growth Including Length, Thickness And Darkness |
| U-1209 |
Treatment Of Human Immunodeficiency Virus (Hiv) Infection In Adult Patients, And Treatment Of Human Immunodeficiency Virus (Hiv) Infection In Pediatric Patients 3 Years Of Age And Older |
| U-121 |
Method Of Treating Conditions Mediated Through Histamine H2-Receptors |
| U-1210 |
Use Of Revlimid (Lenalidomide) While Preventing The Exposure Of A Fetus Or Other Contraindicated Individual To Revlimid (Lenalidomide) |
| U-1211 |
Use Of Revlimid (Lenalidomide) To Inhibit The Secretion Of Pro-Inflammatory Cytokines, Including Tumor Necrosis Factor Alpha |
| U-1212 |
Use Of Revlimid (Lenalidomide) For The Treatment Of Multiple Myeloma And Transfusion-Dependent Anemia In Myelodysplastic Syndromes (Mds) |
| U-1213 |
Topical Treatment Of Seborrheic Dermatitis In Immunocompetetent Patients 12 Years Of Age And Older |
| U-1214 |
Methof For Relieving Constipation In A Human Patient That Comprises Administering To The Patient A Dosage Unit Comprising (I) 24mcg+/- 10% Of A Drug Substance And (Ii) A Pharmaceutically Suitable Excipient |
| U-1215 |
Use Of Revlimid (Lenalidomide) For The Treatment Of Transfusion-Dependent Anemia In Myelodysplastic Syndromes (Mds) |
| U-1216 |
Use Of Revlimid (Lenalidomide) For The Treatment Of Multiple Myeloma |
| U-1217 |
Method Of Increasing Hair Growth |
| U-1218 |
Method Of Stimulating Hair Growth |
| U-1219 |
Method Of Increasing The Number Of Hairs |
| U-122 |
A Therapeutic Method For Controlling Thrombosis |
| U-1220 |
Treatment Of Renal Cell Carcinoma |
| U-1221 |
To Stimulate The Immune System To Induce T Cell Proliferation |
| U-1222 |
To Inhibit The Proliferative Activity Of Neoplastic Cells |
| U-1223 |
Method For Treating Type 2 Diabetes Using A Sustained-Release Composition Containing Exenatide |
| U-1224 |
Reductions In Body Weight Are Observed With Exenatide |
| U-1225 |
Accelerating The Time To Upper And Lower Gastrointestinal Recovery Following Partial Large Or Small Bowel Resection Surgery With Primary Anastomosis |
| U-1226 |
A Method Of Providing A Predetermined Concentration Of Nitric Oxide To A Patient |
| U-1227 |
Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Metformin Hcl Extended Release Is Appropriate |
| U-1228 |
Method Of Treating Type 2 Diabetes Mellitus In Patients For Whom Treatment With Both Sitagliptin And Metformin Hcl Extended Release Is Appropriate Alone Or In Combination With Insulin |
| U-1229 |
Treatment Of Mildly To Moderately Active Ulcerative Colitis In Male Patients |
| U-123 |
Method For Controlling Thrombosis And Decreasing Blood Hypercoagulation And Hemorrhaging Risks |
| U-1230 |
A Method Of Providing Nitric Oxide Therapy To A Patient |
| U-1231 |
Treatment Of Moderate-To-Severe Primary Restless Leg Syndrome In Adults |
| U-1232 |
Use As Anticoagulant In Pts W/ Unstable Angina Undergoing Ptca; W/ Provisional Use Of Glycoprotein Iib/Iiia Inhibitor, As Anticoagulant In Pts Undergoing Pci And For Pts W/, Or At Risk Of, Hit/Hitts Undergoing Pci.Intented For Use W/Aspirin |
| U-1233 |
Treatment Of Chronic Hepatitis C (Chc) Genotype 1 Infection, Administered With Food |
| U-1234 |
For Reducing Total Cholesterol (Total-C), Ldl-C, Apo-Lipoprotein B, Or Total Triglycerides, And Treating Hypertriglyceridemia |
| U-1235 |
Reduction Of Elevated Intraocular Pressure In Patients With Glaucoma Or Ocular Hypertension |
| U-1236 |
Use Of Thalomid (Thalidomide) For The Treatment Of Multiple Myeloma |
| U-1237 |
Combo W/ Other Antiretrovirals For Tx Of Hiv-1 In Antiretroviral Tx-Experienced Pt 6 Years Up, Who Have Evidence Of Viral Replication And Hiv-1 Strains Resistant To Non-Nucleoside Reverse Transcriptase Inhibitor And Other Antiretrovirals |
| U-1238 |
Treatment Of Anemia Due To Chronic Kidney Disease |
| U-1239 |
Magnetic Resonance Imaging Of The Liver |
| U-124 |
Treatment Of Acne |
| U-1240 |
Treatment Of Heavy Menstrual Bleeding In Women Without Organic Pathology Who Choose To Use An Oral Contraceptive As Their Method Of Contraception |
| U-1241 |
Management Of Moderate To Severe Pain By Orally Administering An Intact Composition As Claimed |
| U-1242 |
Prevention Of Respiratory Distress (Rds) In Premature Infants |
| U-1243 |
With Dry Hands, Gently Remove The Suprenza (Phentermine Hydrochloride Odt) Tablet From The Bottle. Immediately Place The Suprenza Tablet On Top Of The Tongue Where It Will Dissolve, Then Swallow With Or Without Water |
| U-1244 |
Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-4 Inhibitor In Combination With Sulfonlyurea |
| U-1245 |
Method Of Treating Type 2 Diabetes Mellitus By Administering A Dipeptidyl Peptidase-4 Inhibitor In Combination With Pioglitazone |
| U-1246 |
Single Dose Administration Into The Surgical Site To Produce Postsurgical Analgesia |
| U-1247 |
Management Of Postherpetic Neuralgia (Phn) In Adults |
| U-1248 |
Use Of Topical Diclofenac On The Knee And A Second Topical Medication On The Same Knee |
| U-1249 |
Treatment Of Male Patient Having A Disease Or Condition Responsive To A Teratogenic Drug |
| U-125 |
Treatment Neurogenerative Diseases |
| U-1250 |
Treatment Of Pain, Including Neuropathic Pain Associated With Diabetic Peripheral Neuropathy Or Spinal Cord Injury, Postherpetic Neuralgia, And Fibromyalgia |
| U-1251 |
A Method Of Controlling Postoperative Ocular Pain And Burning/Stinging In A Patient |
| U-1252 |
Method For Chronic Weight Management By Decreasing Food Intake |
| U-1253 |
Method For Chronic Weight Management By Inducing Satiety |
| U-1254 |
Method For Chronic Wieght Management By Controlling Weight Gain |
| U-1255 |
Method For Chronic Weight Management By Treating Obesity |
| U-1256 |
Treatment Of Seborrheic Dermatitis |
| U-1257 |
Treatment Of Ophthalmic Disorders |
| U-1258 |
Visualization During Vitrectomy Procedures |
| U-1259 |
Prophylaxis Of Hiv-1 Infection |
| U-126 |
Treatment Of Gastritis |
| U-1260 |
Treatment Of Patients With Multiple Myeloma Who Have Received At Least Two Prior Therapies Including Bortezomib And An Immunomodulatory Agent And Have Demonstrated Disease Progression On Or Within 60 Days Of Completion Of The Last Therapy |
| U-1261 |
Reduction Of The Risk Of Hospitalization For Atrial Fibrillation |
| U-1262 |
Use Of Qsymia (Phentermine And Topiramate) For Weight Management, Including, But Not Limited To Effecting Weight Loss, Treating Obesity, And/Or Treating Overweight |
| U-1263 |
Treatment Of Chronic Obstructive Pulmonary Disease (Copd) Or Chronic Bronchitis |
| U-1264 |
Treatment Of A Respiratory Disease |
| U-1265 |
Patented Method Of Using Repaglinide In Combination With Metformin As Indicated For Improving Glycemic Control In Adults With Type 2 Diabetes Mellitus |
| U-1266 |
Method Of Treating Middle-Of-The-Night Insomnia |
| U-1267 |
Treatment Of Rheumatoid Arthritis By Delayed Release Formulation Of 1mg Or 2mg Of Prednisone |
| U-1268 |
Treatment Of Pulmonary, Gastrointestinal And/Or Rheumatological Diseases Or Conditions By Use Of Delayed Release Formulations Of 1mg Or 2mg Prednisone |
| U-1269 |
Treatment Of Rheumatologic, Allergic, Pulmonary, Gastrointestinal, Dermatologic Diseases Or Conditions By The Use Of A Delayed Release 5mg Prednisone Tablet |
| U-127 |
Method Of Producing Neuromuscular Blockade |
| U-1270 |
Method Of Treating Type 2 Diabetes Mellitus By Administering Linagliptin In Combination With Insulin (With Or Without Metformin And/Or Pioglitazone) |
| U-128 |
Method For Treatment Of Tumors |
| U-129 |
Method To Destroy Or Impair Target Cells |
| U-13 |
A Method For Treating Anxiety In A Human Subject In Need Of Such Treatment |
| U-130 |
Management Of Patients With Mastocytosis |
| U-131 |
Photodamaged Skin |
| U-132 |
Inhibiting Hiv Protease |
| U-133 |
Management Of Obesity Including Weight Loss And Maintenance In Patients On A Reduced-Calorie Diet |
| U-134 |
Treatment Of Acne Vulgaris |
| U-135 |
Antitumor Agent |
| U-136 |
Process For Waste Nitrogen Removal |
| U-137 |
Method Of Treating Bacterial Vaginosis |
| U-138 |
Treatment Of Allergic Rhinitis |
| U-139 |
Treatment Of Allergic Reactions |
| U-14 |
Adjunctive Therapy For The Prevention And Treatment Of Hyperammonemia In The Chronic Management Of Patients With Urea Cycle Enzymopathies |
| U-140 |
Use Of Norvir To Inhibit Hiv Protease Or To Inhibit An Hiv Infection |
| U-141 |
Treatment Of Ulcerative Colitis |
| U-142 |
Method Of Treating Allergic Reactions In A Mammal By Using This Active Metabolite |
| U-143 |
Biodegradable Superparamagnetic Metal Oxides As Contrast Agents For Mr Imaging |
| U-144 |
Biologically Degradable Superparamagnetic Materials For Use In Clinical Applications |
| U-145 |
Biologically Degradable Superparamagnetic Particles For Use As Nuclear Magnetic Resonance Imaging Agents |
| U-146 |
Method Of Treating Susceptible Neoplasms In Mammals |
| U-147 |
Detection Of Gastrointestinal Disorders And The Subsequent Breath Collection And Measurement Of 13co2 |
| U-148 |
Device For Collecting A Breath Sample |
| U-149 |
Method Of Treating An Animal, Including A Human Suffering From Or Susceptible To Psychosis, Acute Mania Or Mild Anxiety States |
| U-15 |
Method Of Lowering Intraocular Pressure |
| U-150 |
Method Of Use For Controlling Hyperglycemia By Administration Of This Sustained Release Dosage Form Of Glipizide |
| U-151 |
Relief Of Symptoms Of The Common Cold |
| U-152 |
Method Of Treating Anxiety Related Disorders Including Obsessive Compulsive Disorder |
| U-153 |
Treatment Of Initial Episode Genital Herpes |
| U-154 |
Method Of Treating Animals Suffering From An Appetite Disorder |
| U-155 |
Treatment Of Erectile Dysfunction |
| U-156 |
Method Of Providing Anesthesia |
| U-157 |
Treatment Of A Human Suffering From Vitamin B12 Deficiency |
| U-158 |
Angina |
| U-159 |
Treatment Of Interstitial Cystitis |
| U-16 |
Use In Lung Scanning Procedures |
| U-160 |
Treatment Of Bacterial Infectious Disease |
| U-161 |
Method Of Inhibiting Cholesterol Biosynthesis In A Patient |
| U-162 |
Method Of Use To Inhibit Cholesterol Synthesis In A Human Suffering From Hypercholesterolemia |
| U-163 |
Method Of Using Troglitazone To Treat Impaired Glucose Tolerance To Prevent Or Delay The Onset Of Noninsulin-Dependent Diabetes Mellitus |
| U-164 |
Method Of Using Troglitazone To Prevent Or Delay The Onset Of Noninsulin-Dependent Diabetes Mellitus In A Defined Population Of Patients |
| U-165 |
Treatment Of Symptomatic Benign Prostatic Hyperplasia |
| U-166 |
Treatment Of H.Pylori-Associated Duodenal Ulcer |
| U-167 |
Method For Treating Hiv-1 Infection |
| U-168 |
Method Of Inhibiting Lipoxygenase Activity In A Mammal Which Is The Mode Of Action In The Treatment Of Asthma |
| U-169 |
Methods Of Using The Compound/Drug Product As A Contrast Agent In Magnetic Resonance Imaging |
| U-17 |
Treatment Of Ventricular And Supraventricular Arrhythmias |
| U-170 |
Method Of Obtaining An Mr Image Using The Composition/Drug Product As A Contrast Agent |
| U-171 |
Methods Of Using The Compound/Drug Product As An Oral Contrast Agent In Magnetic Resonance Imaging Of The Gastrointestinal Tract |
| U-172 |
Treatment Of Genital Warts |
| U-173 |
Administration To A Host Suffering From Gestational Diabetes |
| U-174 |
Use As An Antihistamine Agent |
| U-175 |
Method Of Treating Malignant Tumors |
| U-176 |
Method Of Treating A Patient Suffering From Listed Conditions, Including Specific Psychoses |
| U-177 |
Fungicide |
| U-178 |
Facilitated Adherence Of Agents To Skin |
| U-179 |
Enhanced Cutaneous Penetration Of A Dermally-Applied Pharmacologically Active Agent |
| U-18 |
Method For Inhibiting Gastric Secretion In Mammals |
| U-180 |
Treatment Of Adult And Pediatric Patients (Over 6 Months Of Age) With Advanced Hiv Infection |
| U-181 |
Producing Alpha Adrenergic Antagonistic Action In A Host |
| U-182 |
Use Of Salmeterol In Patients With Reversible Airway Obstruction |
| U-183 |
Treatment Of Conditions Caused By Disturbance Of Neuronal 5ht Function |
| U-184 |
Treating Allergic Eye Diseases In Humans |
| U-185 |
Method Of Treating Hypertension |
| U-186 |
Method For Treating Gi Disorders Caused By H.Rylori Which Comprises Administration Of Ranitidine Bismuth Citrate And Clarithromycin For A Greater Than Additive Effect |
| U-187 |
Therapeutic Treatment Of Calcific Tumors |
| U-188 |
Treatment Of H.Pylori Associated Duodenal Ulcer |
| U-189 |
Enhancement Of The Bioavailability Of The Drug Substance |
| U-19 |
Treatment Of Inflammation |
| U-190 |
Use Of Ritonavir In Combination With Any Reverse Transcriptase Inhibitor |
| U-191 |
Method Of Treatment For Controlling And Lowering Intraocular Pressure In A Human |
| U-192 |
Use In Treating Allergic Reactions |
| U-193 |
Psoriasis |
| U-194 |
Treating Angina Pectoris And High Blood Pressure |
| U-195 |
Method For The Diagnosis Of Gastrointestinal Disorders By Urea Isotoac Or Nitrogen Labeled Carbon |
| U-196 |
Treatment Of Metastatic Breast Cancer In Postmenopausal Women With Estrogen Receptor Positive Tumors |
| U-197 |
Use In Combination With Certain Lhrh Analogues For The Treatment Of Advanced Prostate Cancer |
| U-198 |
Treatment Metastatic Carcinoma Of Ovary After 1st Line Failure Or Subsquent Chemotherapy, Treatment Of Breast Cancer After Failure Of Combination Chemotherapy For Metastatic Disease And 2nd Line Treatment Of Aids Related Kaposi's Sarcoma |
| U-199 |
Method Of Treating Infectious Upper Gi Tract Disorders Caused By Campylobacter Pyloridis Infection Comprising Administration Of A Bismuth Agent And An Antimicrobial Agent |
| U-2 |
Treatment Or Prophylaxis Of Angina Pectoris And Arrhythmia |
| U-20 |
A Process For Treating A Patient Suffering From Parkinson's Syndrome And In Need Of Treatment |
| U-200 |
Method Of Treating Gi Disorders Comprising Administration Of A Bismuth-Containing Agent And H2 Receptor Blocking Anti-Secretory Agent |
| U-201 |
Method Of Treating Gi Disorders Comprising Administration Of Campylobacter-Inhibiting Antimicrobial Agent And H2 Receptor Blocking Anti-Secretory Agent |
| U-202 |
Method Of Treating Peptic Ulcer Disease Caused By Campylobacter Pyloridis Comprising Oral Administration Of 50 To 5,000mg Bismuth Daily For 3-56 Days |
| U-203 |
Treatment Of Advanced Breast Cancer In Postmenopausal Women With Disease Progression Following Antiestrogen Therapy |
| U-204 |
Use Of Taxol In Combination With G-Csf For Treatment Of Patients With Aids-Related Kaposi's Sarcoma |
| U-205 |
Method For Treating Heartburn |
| U-206 |
Method Of Using Fsh Alone, Without The Presence Of Exogeneous Lh, In In Vitro Fertilization |
| U-207 |
Use As Nasal Spray |
| U-208 |
Vaginal Administration Using Specified Formulation |
| U-209 |
Vaginal Administration Of Progesterone Using Specified Formulation |
| U-21 |
Treatment Of Humans Suffering Undesired Urotoxic Side Effects Caused By Cytostatically Active Alkylating Agents |
| U-210 |
Method Of Treating Congestive Heart Failure |
| U-211 |
Use In Patients With Reversible Airway Obstruction |
| U-212 |
Method Of Treatment Of Parkinson's Disease |
| U-213 |
Method Of Inhibiting Cholesterol Biosynthesis And Treating Hypercholesterolemia And Method For Treating Hyperlipidemia |
| U-214 |
Use As A Blood Glucose-Lowering Agent |
| U-215 |
Treatment Of Epilepsy Twice Daily. Treating A Patient By Administering Carbamazepine In A Dosage Form Capable Of Maintaining Blood Concentration From 4-12mcg/Ml Over 12 Hours |
| U-216 |
Treatment Of Adenocarcinoma, Including Stage B2-C By Administering An Agonist Of Lh-Rh And Flutamide |
| U-217 |
Method Of Producing Anesthesia |
| U-218 |
Method For Limiting The Potential For Microbial Growth In The Drug Product |
| U-219 |
Treatment Of Parkinson's Disease |
| U-22 |
Method Of Combatting Pathologically Reduced Cerebral Functions And Performance Weaknesses, Cerebral Insufficiency And Disorders In Cerebral Circulation And Metabolism In Warm-Blooded Animals |
| U-220 |
Method Of Diagnosis |
| U-221 |
Selective Vasodilation By Continuous Adenosine Infusion |
| U-222 |
Method Of Treating Paget's Disease Using Actonel |
| U-223 |
Treatment Of Bacterial Conjunctivitis Caused By Susceptible Strains Of Microorganisms |
| U-224 |
Controlling Intraocular Pressure |
| U-225 |
Method For Delivery |
| U-226 |
Method Of Enhancing The Dissolution Profile Of A Pharmaceutical From A Solid Dosage Form Containing The Pharmaceutical And Simethicone |
| U-227 |
Nasal Administration |
| U-228 |
Asthma |
| U-229 |
Cardiac Insufficiency (Congestive Heart Failure) |
| U-23 |
Method For Treating Prostatic Carcinoma Comprising Administering Flutamide |
| U-230 |
Prevention Of Acute Cardiac Ischemic Events |
| U-231 |
Use In Parkinson's Disease |
| U-232 |
Method Of Treating Migraine |
| U-233 |
Decreasing Mortality Caused By Congestive Heart Failure |
| U-234 |
Method Of Using Ribavirin To Treat Viral Infections In Mammals |
| U-235 |
Method Of Modulating Th1 And Th2 Response In Activated T Cells Of A Human Comprising Administering Ribavirin To The T Cells In A Dosage Which Promotes The Th1 Response And Suppresses The Th2 Response |
| U-236 |
Treating Male Pattern Baldness With 0.05 To 3.0mg/Day |
| U-237 |
Method Of Performing Nmr Imaging With A Patient Comprising Administering To The Patient An Effective Amount Of Contrast Agent Disclosed In The Claims |
| U-238 |
Imaging A Body Tissue And Subjecting To Nmr Tomography, Administering An Amount Of Pharmaceutical Agent For Affecting The Relaxation Times Of Atoms In Body Tissues Undergoing Nmr Diagnosis, Whereby The Image Contrast In Enhanced.... |
| U-239 |
Treating Or Controlling Ocular Inflamation Which Comprises Topically Administering To Affected Eye A Composition Comprising An Nsaid, A Polymeric Quaternary Ammonium Compound And Boric Acid |
| U-24 |
Method For Treating Prostate Adenocarcinoma Comprising Administering An Antiandrogen Including Flutamide And An Lhrh Agonist |
| U-240 |
Treatment Of Acute Migraine Attacks |
| U-241 |
For Short-Term Treatment Active Duodenal Ulcer, Maintenance Therapy For Duodenal Ulcer Patients At Reduced Dosage After Healing Of Active Ulcer, Short-Term Treatment Active Benign Gastric Ulcer & Gerd, Pathological Hypersecretory Conditions |
| U-242 |
Use Of Follitropin Alpha Alone In In-Vitro Fertilization |
| U-243 |
Topical Administration |
| U-244 |
Platelet Aggregation Inhibitors |
| U-245 |
Treatment Of Seborrhea Dermatitis In Humans |
| U-246 |
Phosphate Binding |
| U-247 |
Treatment Of Rheumatoid Arthritis |
| U-248 |
Treatment Of Hiv |
| U-249 |
Method Of Treating Allergic Or Non-Allergic Rhinitis In Patients By Administering Aerosolized Particles Of Mometasone Furoate |
| U-25 |
Reducing Cholesterol In Cholelithiasis Patients |
| U-250 |
Treatment Of Hepatitis B Infection |
| U-251 |
Use Of Troglitazone In Combination With Sulfonylureas In The Treatment Of Type Ii Diabetes |
| U-252 |
Method Of Treating A Human Subject Having Gaucher's Disease |
| U-253 |
Oral Transmucosal Use |
| U-254 |
Use Of Aggrastat In Combination With Heparin |
| U-255 |
Improved Wakefulness In Patients With Excessive Daytime Sleepiness Associated With Narcolepsy |
| U-256 |
Treatment Of Hiv Infection In Combination With One Or More Additional Hiv Antiviral Agents |
| U-257 |
Treatment Of Hiv Infection |
| U-258 |
Treatment Of Neurodegenerative Diseases |
| U-259 |
Treatment Of Androgenic Alopecia By Oral Administration Drug Substance |
| U-26 |
Reducing Cholesterol Gallstones And/Or Fragments Thereof |
| U-260 |
Reduction Of Intraocular Pressure In Patients With Open Angle Glaucoma And Ocular Hypertension Who Are Intolerant Of Other Iop Lowering Medications Or Insufficiently Responsive To Another Iop Lowering Medication |
| U-261 |
Treating Benign Prostatic Hyperplasia With A Genus Of Compounds, Including Finasteride |
| U-262 |
Treating Benign Prostatic Hypertrophy With Finasteride |
| U-263 |
Method Of Treating A Malignant Condition Through Intravascular Administration Of Busulfan. Method For Treating Leukemia Or Lymphoma In A Patient Undergoing A Bone Marrow Transplant Through Intravenous Administration Of Busulfan |
| U-264 |
Method Of Treating A Malignant Disease Through Parenteral Administration Of Busulfan. Method For Treating A Patient Undergoing A Bone Marrow Transplant Through Intravascular Administration Of Busulfan |
| U-265 |
Use As Laxative |
| U-266 |
Relief Of The Signs And Symptoms Of Osteoarthritis; Relief Of The Signs And Symptoms Of Rheumatoid Arthritis In Adults; Management Of Acute Pain In Adults; Treatment Of Primary Dysmennorrhea; Acute Treatment Of Migraine Attacks In Adults |
| U-267 |
Preventing Heartburn Episodes Following Ingestion Of Heartburn-Inducing Food/Beverage, Comprising Admin To Pt, 30 Min Prior To Consumption By The Pt The Food/Beverage, A Composition Comprising 10mg Famotidine |
| U-268 |
Acromegaly |
| U-269 |
Excess Gh-Secretion Or Gastro-Intestinal Disorders |
| U-27 |
Dissolving Cholesterol Gallstones And/Or Fragments Thereof |
| U-270 |
Method Of Improving The Time For Administration Or The Time Between Changes Of Giving Sets For The Drug Product |
| U-271 |
Method Of Treating Tumors |
| U-272 |
Method Of Treating Carcinoma |
| U-273 |
Cutaneous T-Cell Lymphoma |
| U-274 |
Zanamivir For Inhalation |
| U-275 |
Method Of Use Of The Drug Substance |
| U-276 |
Method Of Use Of Levobupivacaine |
| U-277 |
Neurological And Other Disorders (Treatment Of Epilepsy, Bid Oral Dosing) |
| U-278 |
Method Of Use Of The Indication Of The Drug Product |
| U-279 |
Method Of Use Of The Approved Product |
| U-28 |
Cerebral, Coronary, Peripheral, Visceral And Renal Arteriography, Aortography And Left Ventriculography |
| U-280 |
Treating Precipitated Acute Urinary Retention With Finasteride |
| U-281 |
Antimycotic Uses, Specifically Treatment Of Onychomycosis |
| U-282 |
Method Of Treating Bacterial Infections |
| U-283 |
Method For Treating Menopausal Symptoms In A Postmenopausal Female |
| U-284 |
Menopausal And Postmenopausal Disorders (Including Vasomotor Symptoms Associated With Menopause, And Vulvar And Vaginal Atrophy) And Osteoporosis |
| U-285 |
Depression And Social Anxiety Disorder/Social Phobia |
| U-286 |
Depression |
| U-287 |
Treatment Or Prevention Of Osteoporosis |
| U-288 |
Therapy Of Influenza |
| U-289 |
Treatment Of Non-Hyperkeratotic Actinic Keratoses Of Face And Scalp |
| U-29 |
Ct Imaging Of The Head And Body, And Intravenous Excretory Urography |
| U-290 |
Inhibiting Transplant Rejection Using Rapamycin (Sirolimus) |
| U-291 |
Inhibiting Transplant Rejection Using Rapamycin (Sirolimus) In Combination With Cyclosporin |
| U-292 |
Inhibiting Transplant Rejection Using Rapamycin (Sirolimus) In Combination With Azathioprine |
| U-293 |
Inhibiting Transplant Rejection Using Rapamycin (Sirolimus) In Combination With A Corticosteroid |
| U-294 |
Treatment Of Hyperpigmentary Disorders |
| U-295 |
Treatment Of Seasonal And Perennial Allergic Rhinitis Symptoms |
| U-296 |
Treating Migraine Pain And One Or More Of A Cluster Of Symptoms Characteristic Of A Migraine Attack Symptoms Being Selected From Photophobia, Phonophobia Nausea And Functional Disability |
| U-297 |
Prevention Or Treatment Of Reversible Vasoconstriction By The Inhalation Of Nitric Oxide With An Oxygen Containing Gas |
| U-298 |
Method Of Combating Bacteria In A Patient |
| U-299 |
Treatment Of Adenomatous Polyps |
| U-3 |
Treatment Of Hypertension |
| U-30 |
Cerebral Angiography, And Venography |
| U-300 |
Indicated For The Reduction Of Elevated Total And Ldl Cholesterol Levels In Patients With Primary Hypercholesterolemia |
| U-301 |
Use Of Troglitazone In Combination With Sulfonylureas And Biguanides In The Treatment Of Type Ii Diabetes |
| U-302 |
To Reduce The Risk Of Stroke In Patients Who Have Had Transient Ischemia Of The Brain Or Completed Ischemic Stroke Due To Thrombosis |
| U-303 |
Method Of Use Patent-Product Approved For Treatment Of Osteoporosis, Paget's Disease, Prevention And Treatment Of Glucocorticoid Induced Osteoporosis |
| U-304 |
A Method Of Treatment Of A Condition Involving An Antibody Antigen Reaction |
| U-305 |
Methods For Using The Drug Product |
| U-306 |
Treatment Of Post-Menopausal Urogenital Symptoms Associated With Estrogen Deficiency |
| U-307 |
Claims An Olanzapine Polymorph Useful For Treating Any Number Of Listed Conditions, Including Specific Psychoses,Employing Olanzapine As Per The Indication Of This Nda |
| U-308 |
Claims A Solid Oral Formulation Including Tablets And Granules Of Olanzapine Useful For Treating Any Number Of Listed Conditions, Including Specific Psycholes, Employing Olanzapine As Per The Indications Of This Nda |
| U-309 |
Treating Sjoegren Syndrome |
| U-31 |
Intra-Arterial Digital Subtraction Angiography |
| U-310 |
Treatment Of Xerostomia |
| U-311 |
Hormone Replacement |
| U-312 |
Panic Disorder, Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder |
| U-313 |
Treatment Of Congestive Heart Failure |
| U-314 |
Method For Treating Hyperparathyroidism Which Comprises Suppressing Parathyroid Activity |
| U-315 |
Method For Administering Drug To Gastrointestinal Tract |
| U-316 |
Method Of Treating A Subject Suffering From Prostate Cancer |
| U-317 |
Method Of Using Troglitazone To Treat Patients Having Insulin Resistance |
| U-318 |
Treatment Of Patients With An Overactive Bladder With Symptoms Of Urinary Frequency, Urgency, Or Urge Incontinence |
| U-319 |
Treatment Of Microbial Infections |
| U-32 |
Palliative Treatment Of Patients With Ovarian Carcinoma Recurrent After Prior Chemotherapy, Including Patients Who Have Been Previously Treated With Cisplatin |
| U-320 |
Inhibiting Or Eliminating Acute Myeloid Leukemia |
| U-321 |
Reduction Of Elevated Ipth Levels In The Mgt Of Secondary Hyperparathyroidism In Patients Undergong Chronic Renal Dialysis |
| U-322 |
Treatment Of Alzheimer's Dementia |
| U-323 |
Use As A Bile Acid Sequestrant |
| U-324 |
Method Of Treating An Animal, Including A Human, Suffering From Or Susceptible To Psychosis Or Acute Mania Employing Olanzapine |
| U-325 |
Method Of Treating A Patient Suffering From Any Of A Number Of Listed Conditions, Including "Bipolar Disorder Nos" Employing Olanzapine |
| U-326 |
Method Of Treating Schizophrenia And Bipolar Disorder |
| U-327 |
Method Of Treating A Patient Suffering From Any Of A Number Of Listed Psychotic Conditons Employing Olanzapine |
| U-328 |
Method Of Treating A Patient Suffering From Any Of A Number Of Listed Conditions Including "A Psychotic Condition" Employing An Olanzapine Polymorph |
| U-329 |
Use Of Avandia As Monotherapy, In Combination With Metformin, And In Combination With Sulfonylureas To Improve Glycemic Control In Patients With Type 2 Diabetes Mellitus |
| U-33 |
Treating Viral Infections In A Mammal |
| U-330 |
Treatment Of Nausea And Vomiting |
| U-331 |
Method Of Treating Hyperlipidemia With Nicotinic Acid By Dosing Once Per Day In The Evening Or At Night |
| U-332 |
Treatment Or Prevention Of Bronchospasm |
| U-333 |
Method Of Treating Ocular Hypertension |
| U-334 |
Treatment Of Excessive Female Facial Hair |
| U-335 |
Use Of Pravastatin Sodium For Secondary Prevention Of Coronary Events In Men And Women Who Have Had A Myocardial Infarction And Have Normal Cholesterol Levels |
| U-336 |
Diagnostic Radioimaging |
| U-337 |
Use Of Cardiolite/Miraluma Kit For The Preparation Of Tc99m Sestamibi |
| U-338 |
Methods For Treating Disturbances Of Mood, Disturbances Of Appetite, Depressed Mood, Or Carbohydrate Craving All Associated With Premenstrual Syndrome |
| U-339 |
Prevention Of Cardio-Toxicity Caused By The Administration Of Doxorubicin |
| U-34 |
Treating Viral Infections In A Warm-Blooded Animal |
| U-340 |
The Long Term Treatment Of Growth Failure Due To Lack Of Adequate Endogenous Growth Hormone Secretion In Children |
| U-341 |
Method For Enhancing The Treatment Of ... Late Luteal Phase Dysphoric Disorder |
| U-342 |
Method For Treatment Of Late Luteal Phase Dysphoric Disorder |
| U-343 |
Reduction Of Intestinal Gas, Cramping And Anorectal Irritation |
| U-344 |
Method For Inhibiting Hiv Infection By Administering Ritonavir In Combination With Another Hiv Protease Inhibitor |
| U-345 |
Ritonavir And Another Hiv Protease Inhibitor For Concomitant Administration For The Treatment Of An Hiv Infection |
| U-346 |
Method For Inhibiting Cytochrome P450 Monooxygenase With Ritonavir And A Method For Improving The Pharmcokinetics Of A Drug That Is Mtabolized By Cytochrome P450 Monooxygenase By Admin The Drug And Ritonavir |
| U-347 |
Method Of Use In Combination With Reverse Transcriptase Inhibitors |
| U-348 |
Method Of Use For Inhibiting Hiv Infection |
| U-349 |
Method Of Use Which Is Subject Of The Application |
| U-35 |
Treating Cytomegalovirus In A Human With An Injectable Composition |
| U-350 |
Preparation Of A Pharmaceutical Composition For Concomitant Admin With A Reverse Transcriptase Inhibitor |
| U-351 |
Inhibiting Protease With Lopinavir And Inhibiting An Hiv Infection With Lopinaviir |
| U-352 |
Inhibiting Hiv Infection By Administering Ritonavir In Combination With A Reverse Transcriptase Inhibitor |
| U-353 |
Prevention And Treatment Of Osteoporosis |
| U-354 |
Method Of Treating Hyperlipidemia With Nicotinic Acid Without Causing Treatment-Limiting Elevations In Uric Acid Or Glucose Levels Or Causing Liver Damage, By Dosing Once Per Day In The Evening Or At Night |
| U-355 |
Method Of Assisting Person To Quit Smoking...Transdermally Admin Nicotine Via..Patch Adhered To Skin At Dosing Rate Approx Same As Absorbed From Smoking |
| U-356 |
Delivering A Medicinal Aerosol Formulation Using Cfc-Free Propellant 134a. |
| U-357 |
Use Of The Drug Product In Photodynamic Therapeutic Protocols For The Treatment Of Age-Related Macular Degeneration And Related Conditions Involving Unwanted Neovasculature In The Eye |
| U-358 |
Depression, Obsessive Compulsive Disorder, Panic Disorder And Social Anxiety Disorder |
| U-359 |
Method Of Use Of Visicol |
| U-36 |
Methods Of Treating Bacterial Illnesses |
| U-360 |
Method Of Treating A Patient Suffering From Any Of A Number Of Pathological Psychological Conditions Including Mental Disorders Employing Olanzapine As Per The Indication Which Is The Subject Matter Of This Snda-011 |
| U-361 |
Management Of Anxiety Disorders And The Short-Term Relief Of The Symptoms Of Anxiety |
| U-362 |
Use Of Approved Formulations To Treat All Approved Disease Indications |
| U-363 |
Method Of Treating A Patient Suffering From Any Of A Number Of Pathological Psychological Conditions That Relate To The Use Of A Psychoactive Substance Employing Olanzapine As Per The Indication The Subject Matter Of Supplement 011 |
| U-364 |
Treating A Patient Suffering From Or Susceptible To Any Number Of Listed Conditions Including Psychosis, Employing Olanzapine As Per The Indication Which Is The Subject Matter Of This Snda-011 |
| U-365 |
Method For The Treatment Of Cardiovascular Disease Through The Administration Of A Calcium Blocking Vasodilator In Our Extended, Controlled Release Formulation |
| U-366 |
Method For The Treatment Of Cardiovascular Disease Through The Administration Of A Calcium Blocking Vasodilator In A Delayed Release Formulation |
| U-367 |
Treatment Of Cardiovascular Disorders |
| U-368 |
Heartburn |
| U-369 |
Method Of Controlling And Lowering Intraocular Pressure |
| U-37 |
Method Of Treating Gastrointestinal Disease |
| U-370 |
Intravaginal Treatment Of Vaginal Infections With Buffered Metronidazole Compositions |
| U-371 |
Approval For Marketing Only Under A Special Restriction Program Approved By Fda Called "System For Thalidomide Education And Prescribing Safety" (S.T.E.P.S.) |
| U-372 |
Method For Administering A Beneficial Drug To The Gi Tract Of An Animal, Which Method Comprises Admitting An Osmotic Device Orally Into The Animal... |
| U-373 |
General Use Claim Submitted For 12 Nexium Patients Stating "Pertinent To The Capsule Formulation For Nexium And Its Indications For The Treatment Of Gerd And Eradication Of H.Pylori To Reduce The Risk Of Duodenal Ulcer Recurrence |
| U-374 |
Kit Adapted And Designed To Provide Both Data On The Current Reproductive Status Of A Patient And Contraception For Those Who Are Not Pregnant, But Recently Engaged In Unprotected Sex |
| U-375 |
Method Of Using Ribavirin For Treating A Disease Responsive To Ribavirin, E.G. Hepatitis C |
| U-376 |
Treatment Of Influenza |
| U-377 |
Method Of Treating Pt With Chronic Hepatitis C Having Hcv Genotype 1 And Viral Load Greater Than 2 Million Copies/Ml To Eradicate Detectable Hcv-Rna By Admin Combination Of Ribavirin And Interferon Alfa-2b For A Least 24 Weeks |
| U-378 |
Method For Treating Incontinence |
| U-379 |
Method Of Treating Onychromycosis |
| U-38 |
Treatment Of Paroxysmal Supraventricular Tachycardia |
| U-380 |
Combinations Of Taxol (Paclitaxel) And Cisplatin Which Are Suitable For The Treatment Of Ovarian And Non-Small Cell Lung Carcinomas |
| U-381 |
Treatment Of Hyperphosphatemia |
| U-382 |
Method Of Stablizing Prostaglandin |
| U-383 |
Method For Treating Glaucoma And Ocular Hypertension |
| U-384 |
Treatment Of Cmv Retinitis |
| U-385 |
Treatment Of Peptic Ulcers |
| U-386 |
Treatment Of Patients Suffering From A Late Asthmatic Reaction Or Late Phase Asthma |
| U-387 |
Treatment Of Patients With Respiratory Disorders |
| U-388 |
Smoking Cessation Aid Applied To The Skin |
| U-389 |
Smoking Cessation Aid Applied To The Skin On Waking And Removed Prior To Sleep After About 16 Hours |
| U-39 |
Angina Pectoris |
| U-390 |
Method Of Using The Drug To Treat Neuroimmunologic Diseases (Including Multiple Sclerosis) |
| U-391 |
Use Of Casodex In Combination With Lhrh Agonists For The Treatment Of Prostate Cancer |
| U-392 |
Treatment Of Patients For Inflammation |
| U-393 |
Management Of Incontinence, Mgt Of Hormone Replacement Therapy, Treatment Of Involuntary Incontinence, Mgt Overactive Bladder And Increasing Compliance In Such Pt |
| U-394 |
Method Of Use Of Alphagan |
| U-395 |
Method Of Use Of Alphagan P |
| U-396 |
Method Of Treating People Suffering From Depression |
| U-397 |
Method Of Treating People Suffering From Depression Without An Increase In Nausea |
| U-398 |
Treatment Of Generalized Anxiety Disorder |
| U-399 |
In-The-Eye Use Of Chlorine Dioxide Containing Compositions |
| U-4 |
Providing Prevention And Treatment Of Emesis And Nausea In Mammals |
| U-40 |
Method Of Treatment Of Burns |
| U-400 |
Use Of Ribavirin To Increase Type 1 Cytokine Response And Suppress Type 2 Cytokine Resp0nse To Lymphocytes, Including Methods That Take Advantage Of Such Modulation To Treat Infections And Infestations |
| U-401 |
Use Of Lopinavir In Combination With Reverse Transcriptase Inhibitors For Treating Hiv Infection And In Combo With Other Hiv Protease Inhibitors |
| U-402 |
Treatment Of Actinic Keratoses |
| U-403 |
Anti-Allergic For Various Allergic Diseases |
| U-404 |
Treatment Of Allergic Conjunctivitis |
| U-405 |
For Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome (Ibs) |
| U-406 |
Method Of Use Of Atovaquone And Proguanil |
| U-407 |
Method Of Treating Otopathy |
| U-408 |
For Inducing Ovulation In Conjunction With A Gonadotropin Releasing Factor Antagonist And Recruiting Oocytes For In-Vitro Fertilization |
| U-409 |
Method Of Treating Inflammation Using Drug Substance |
| U-41 |
Method Of Treating Cardiac Arrhythmias |
| U-410 |
Method Of Reducing Amount Of Respective Active Components Administered To A Diabetic Patient By Administering A Chemical Compound Having A Particular Formula (Including Pioglitazone) In Combination With An Insulin Secretion Enhancer |
| U-411 |
Method Of Reducing The Side Effects Of Active Components Administered To A Diabetic Patient By Administering A Chemical Compound Having A Particular Formula (Which Includes Pioglitazone) In Combination With An Insulin Preparation |
| U-412 |
Treatment Of Type 2 Diabetes |
| U-413 |
Use Of The Active Ingredient For Inhibiting The Biosynthesis Of Cholesterol And Treatment Of Atherosclerosis |
| U-414 |
A Method Of Treating Glycometabolism Disorders By Administering An Insulin Sensitivity Enhancer (Including Pioglitazone) In Combination With A Biguanide |
| U-415 |
A Method For Reducing The Amount Of Active Components Administered To A Diabetic Patient By Administering An Insulin Sensitivity Enhancer (Including Pioglitazone) In Combination With A Biguanide As Said Active Components |
| U-416 |
A Method For Reducing Side Effects Of Active Components Administered To A Diabetic Patient By Administering An Insulin Sensitivity Enhancer (Including Pioglitazone) In Combination With A Biguanide As Said Active Components |
| U-417 |
Combination Use Of Ad-4833 With A Biguanide |
| U-418 |
A Method Of Treating Lipid Metabolism Disorders By Administering A Chemical Compound Having A Particular Formula (Which Includes Pioglitazone) In Combination With An Insulin Secretion Enhancer |
| U-419 |
A Method Of Treating Lipid Metabolism Disorders By Administering An Insulin Sensitivity Enhancer (Including Pioglitazone) In Combination With A Biguanide |
| U-42 |
Adjuvant Treatment In Combination With Fluorouracil After Surgical Resection In Patients With Dukes' Stage C Colon Cancer |
| U-420 |
Method Of Treatment Of Type Ii Diabetes |
| U-421 |
Use For Sedation |
| U-422 |
Method Of Treating At Least One Of Attention Deficit Disorder And Attention Deficit Hyperactivity Disorder |
| U-423 |
Method Of Treating At Least One Of Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, Or Aids Related Dementia |
| U-424 |
For Once Daily, Bolus Administration To A Patient In Order To Engender Treatment For A Nervous Disorder For Substantially An Entire Day On A Chronic Basis |
| U-425 |
Method Of Reducing Side Effects Of Active Components Admin To A Diabetic By Admin A Chemical Compound Having Formula (Incl Pioglitazone) In Combination With An Insulin Secretion Enhancer |
| U-426 |
Prevention Of Premature Lh Surges In Women Undergoing Controlled Ovarian Stimulation |
| U-427 |
Method Of Treating Allergic Reactions In Mammals |
| U-428 |
Method Of Treating Allergy In A Mammal Using This Active Metabolite |
| U-429 |
Method Of Using Desloratadine To Treat Allergic Rhinitis |
| U-43 |
Management Of Chronic Pain In Patients Requiring Opioid Analgesia |
| U-430 |
Method Of Treating A Diabetic By Administering An Insulin Sensitizer In Combination With An Insulin Secretion Enhancer, And A Drug Product C0mprising An Insulin Sensitizer And An Insulin Secretion Enhancer |
| U-431 |
Posttraumatic Stress Disorder |
| U-432 |
Reduction Of Atherosclerotic Events (Myocardial Infarction, Stroke, And Vascular Death) In Patients With Atherosclerosis Documented By Recent Stroke, Recent Myocardial Infarction Or Established Peripheral Arterial Disease |
| U-433 |
Use Of Levocaritine In Prevention And Treatment Of Carnitine Deficiency In Patients With End Stage Renal Disease Who Are Undergoing Dialysis |
| U-434 |
Controlled Symptoms Of Diarrhea, Bloating Pressure And Cramps, Commonly Referred To As Gas |
| U-435 |
A Titration Dosing Regimen For The Treatment Of Pain Using An Initial Dose Of About 25mg |
| U-436 |
Acute Treatment Of Migraine Attacks With Or Without Aura In Adults |
| U-437 |
Method Of Use Equal To Process Of Preparation |
| U-438 |
Treatment/Prevention Of Neurodegenerative Disease |
| U-439 |
Treatment Of Obesity |
| U-44 |
Relief Of Nausea And Vomiting |
| U-440 |
Method For Transdermal Administration Of A Drug Through Non-Scrotal Skin Using A Transdermal Drug Delivery Device Containing The Drug And Having An Adhesive Surface |
| U-441 |
Method Of Treating Ms By Administering Copaxone |
| U-442 |
Method For Delivering A Drug To A Patient In Need Of The Drug, While Avoiding The Occurence Of An Adverse Side Effect Known Or Suspected Of Being Caused By Said Drug |
| U-443 |
Management Of Moderate To Severe Pain When A Continuous, Around-The-Clock Analgesic Is Needed For An Extended Period Of Time |
| U-444 |
Treatment Of Migraine |
| U-445 |
Use As An Antimycotic Agent |
| U-446 |
Topical Treatment Of Ocular Hypertension And Glaucoma |
| U-447 |
Method Of Treating Hyperlipidemia With Nicotinic Acid By Dosing Once Per Day In The Evening Or At Night |
| U-448 |
Method Of Treating Hyperlipidemia With Nicotinic Acid Without Causing Treatment-Limiting Elevations In Uric Acid Or Glucose Levels Or Causing Liver Damage, By Dosing Once Per Day In The Evening Or At Night |
| U-449 |
Use In Combination With 5-Fluorouracil And Leucovorin For The Treatment Of Metastatic Colorectal Cancer Where The Dose Of Leucovorin Is At Least 200mg Per Square Meter |
| U-45 |
Treatment Of Inflammation And Analgesia |
| U-450 |
Intermediate Rel Nicotinic Acid Formulations Having Unique Urinary Metab Profiles Resulting From Absorption Profiles Of Nicotinic Acid From The Intermediate Nicotinic Acid Formulations,Suitable For Tx Hyperlipidemia Following Qd Dosing |
| U-451 |
Treatment Of Depression And Generalized Anxiety Disorder |
| U-452 |
Use Of Lansoprazole For Combatting Diseases Caused By The Genus Campylobacter (C.Pylori=H.Pylori) |
| U-453 |
Treatment Of Platelet Associated Ischemic Disorders |
| U-454 |
Method Of Tx A Pt Suspected Of Having Hepatitis C By Admin, In Combination, A Conjugate Comprising Peg 12000 & Interferon Alfa-2b In An Amt Of From 0.5mcg/Kg To 2mcg/Kg, Once Weekly, And Ribavirin |
| U-455 |
Treatment Of Pulmonary Hypertension With Ut-15 |
| U-456 |
Method Of Decreasing The Production Of A-Beta Using A Composition Which Decreases Blood Cholesterol In Patients At Risk Of Or Exhibiting Symptoms Of Alzheimer's Disease |
| U-457 |
Method Of Treating A Vaginal Fungal Infection In A Female Human |
| U-458 |
Method Of Use Of Imagent |
| U-459 |
Treatment Of Depression And Generalized Anxiety Disorder |
| U-46 |
Treatment Of Panic Disorder |
| U-460 |
Method Of Treating Psychiatric Symptoms Associated With Premenstrual Disorders Using Sertraline |
| U-461 |
Method Of Treatment Of Late Luteal Phase Dysphoric Disorder (Pmdd) Using Sertraline |
| U-462 |
Signs And Symptoms Of Osteoarthritis And Adult Rheumatoid Arthritis And Treatment Of Primary Dysmenorrhea |
| U-463 |
Venography |
| U-464 |
Peripheral Arteriography |
| U-465 |
Ct Imaging Of The Head |
| U-466 |
Treatment Of Irritable Bowel Syndrome |
| U-467 |
Use Of Eplerenone In Combination With An Angiotensin Converting Enzyme (Ace) Inhibitor For Treating Hypertension |
| U-468 |
Method Of Using Fexofenadine Hcl In Treating Allergic Rhinitis |
| U-469 |
Treatment Of Gastroesophageal Reflex Disease (Gerd) And Eradication Of H.Pylori To Reduce Risk Of Duodenal Ulcer Recurrence |
| U-47 |
Stimulation Of The Release Of Growth Hormone |
| U-470 |
Therapy In Chronic Hepatitis B Virus Infection |
| U-471 |
Method Of Treating A Patient Suffering From Diabetes Mellitus |
| U-472 |
Treatment Of Attention Deficit Hyperactivity Disorder Using Methylphenidate Bi-Modal Release Profile Extended-Release Capsules |
| U-473 |
To Reduce Plasma Cholesterol Levels In A Mammal |
| U-474 |
To Reduce Plasma Cholesterol Levels By Admin Ezetimibe In Combo With Cholesterol Biosynthesis Inhib Selected From Group Consisting Of Hmg Coa Reductase Inhibitors Incl Simvastatin |
| U-475 |
Treatment Of Cutaneous Manifestations Of Cutaneous T-Cell Lymphoma In Patients Who Are Refractory To At Least One Prior Systemic Therapy |
| U-476 |
Method Of Treating Androgen Responsive/Mediated Condition In Mammal By Admin A Safe, Effective Amount Of Dutasteride Or Pharmaceutically Acceptable Derivative Thereof..Conditions Include Benign Prostatic Hypertrophy |
| U-477 |
Method Of Inhibiting 5 Alpha Testosterone Reductase Enzyme With Dutasteride Or Its Derivative And Treating Androgen Responsive/Mediated Disease Including Benign Prostatic Hyperplasia |
| U-478 |
Method Of Treating Hepatitis C Viral Infection By Continuous Parenteral Admin Interferon Alpha 2-10 Million Iu Weekly, Subcutaneously, Injection Of Polymer-Interferon Alpha Conjugate-Polymer Is Peg-Interferon Is Alpha 2b |
| U-479 |
Method Of Using Peg-Intron/Rebetol Combination Therapy And Intron/Rebetol Combination Therapy |
| U-48 |
Analgesia |
| U-480 |
Contrast Agent For Mri |
| U-481 |
Disubstituted Acetylenes Bearing Heteroaromatic And Heterobicyclic Groups Having Retinoid-Like Activity |
| U-482 |
Method Of In Vitro Fertilization Therapy Including Means For Inducing Ovulation.... |
| U-483 |
Method For The Administration Of Drugs Using That Compound |
| U-484 |
Method Of Treating A Skin Disease With A Corticosteroid-Containing Pharmaceutical Composition |
| U-485 |
Method And Composition For Reducing Nerve Injury Pain Associated With Shingles (Herpes Zoster And Post-Herpetic Neuralgia) |
| U-486 |
External Preparation For Application To The Skin Containing Lidocaine-Drug Retaining Layer Placed On Support And Comprises Adhesive Gel Base 1-10% By Weight Of Lidocaine |
| U-487 |
Method And Composition For Reducing Nerve Injury Pain Associated With Shingles (Herpes Zoster And Post-Herpetic Neuralgia) |
| U-488 |
Method For Reducing The Pain Associated With Herpes-Zoster And Post-Herpetic Neuralgia |
| U-489 |
Expectorant |
| U-49 |
Symptomatic Cancer-Related Hypercalcemia |
| U-490 |
Testosterone Replacement Therapy In Males For Conditions Associated With A Deficiency Or Absence Of Endogenous Testosterone |
| U-491 |
Method Of Delivering A Drug To The Lung |
| U-492 |
Method For The Treatment Of Skin, Suffering From A Condition Selected From A Group Consisting Of Nonacne Inflammatory Dermatoses... Comprising Applying To Affected Area. A Therapeutically Effective Amt Azelaic Acid |
| U-493 |
Treatment Of Type 2 Diabetes Mellitus |
| U-494 |
Treatment Of Attention-Deficit Hyperactivity Disorder |
| U-495 |
Peritoneal Dialysis Solution |
| U-496 |
Method For Treating Chronic Renal Failure |
| U-497 |
Relief Of The Signs And Symptoms Of Osteoarthritis And Rheumatoid Arthritis |
| U-498 |
Intra-Arterial And Intravenous Uses Of Ultravist |
| U-499 |
Method Of Using Rebetol Capsules In Combination With A Conjugate Comprising Polyethylene Glycol(Peg) And An Alpha Interferon, Including, For Example, Peg-Intron Powder For Injection |
| U-5 |
Method Of Producing Bronchodilation |
| U-50 |
Use In Treating Inflammatory Dermatoses |
| U-500 |
Use As An Antihypertensive Agent |
| U-501 |
Treatment Of Recurrent Herpes Labialis (Cold Sores) In Adults |
| U-502 |
Pityriasis Versicolor |
| U-503 |
Generator Must Be Used With Infusion System Specifically Labeled For Use With Generator |
| U-504 |
Tinea Pedis, Tinea Cruris, Tinea Corporis |
| U-505 |
Ultrasound Contrast Agent |
| U-506 |
Pharm Product Container 1st Chamber Is Disposed Aqueous Diluent Sol 2nd Chamber Pharm Active Agent Comprising Acetylcholine,Buffer In 1st Cham Is Sufficient To Buffer Ph Of Mixed Sol Resulting Mixture Of Aqueous Diluent Sol & Pharm Active.. |
| U-507 |
Acromegaly In Patients W/Inadequate Response To Surgery And/Or Radiation Therapy And/Or Medical Therapies, Or For Whom These Therapies Are Not Appropriate |
| U-508 |
Method Of Releasing 17-Beta Oestradiol Precursor In A Substantially Zero Order Pattern For At Least Three Weeks |
| U-509 |
Treatment Of Cutaneous Manifestations Of Cutaneous T-Cell Lymphoma In Patients Who Are Refractory To At Least One Prior Systemic Therapy |
| U-51 |
Blood Pool Imaging, Including Cardiac First Pass And Gated Equilibrium Imaging And For Detection Of Sites Of Gastrointestinal Bleeding |
| U-510 |
Topical Treatment Of Cutaneous Lesions In Patients With Cutaneous T-Cell Lymphoma (Stage Ia And Ib) Who Have Refractory Or Persistent Disease After Other Therapies Or Who Have Not Tolerated Other Therapies |
| U-511 |
Use Of Quinolone Compounds Against Anaerobic Pathogenic Bacteria |
| U-512 |
Use Of Quinolone Compounds Against Atypical Upper Respiratory Pathogenic Bacteria |
| U-513 |
Methods Of Use Of Antimicrobial Compounds Against Pathogenic Amycoplasma Bacteria |
| U-514 |
Prevention Of Ovulation In A Woman |
| U-515 |
Treatment Of Multiple Myeloma Patients Who Have Received At Least Two Prior Therapies And Have Demonstrated Disease Progression On The Last Therapy |
| U-516 |
Method Of Treating A Psychotic Disease |
| U-517 |
Stable Gel Formulation For Topical Treatment Of Skin Conditions |
| U-518 |
Obsessive Compulsive Disorder |
| U-519 |
Post Operative Nausea And Vomiting |
| U-52 |
Treatment Of Adult And Pediatric Patients(Over Six Months Of Age) With Advanced Hiv Infection |
| U-520 |
Premenopausal Osteoporosis |
| U-521 |
Method Of Using Ribavirin In Combination With Intron A (Interferon Alpha-2 B Recombinant) Injection To Treat Patients With Chronic Hepatitis C |
| U-522 |
Treatment Of Cmv Retinitis By Intravitreal Admin Of A Phosphorothioate Oligonucleotide Capable Of Hybridizing With Cmv Mrna |
| U-523 |
Method Of Treating Infection By Cryptosporidium Parvum In An Immunocompromised Mammal |
| U-524 |
Method Of Treating Diarrhea |
| U-525 |
Method Of Treating Parasitic Infections |
| U-526 |
Method Of Providing Controlled Release Of A Treating Agent Using A Controlled Release Composition |
| U-527 |
Method Of Delivering An Active Ingredient Using A Progressive Hydration Bioadhesive |
| U-528 |
Prevention Of Chemotherapy-Induced Nausea And Vomiting |
| U-529 |
Once Daily Treatment Of Asthma With Nebulized Budesonide |
| U-53 |
Hypercalcemia Of Malignancy |
| U-530 |
Treatment Of Herpes Zoster, Treatment Of Genital Herpes, Treatment Of Cold Sores, Suppression Of Genital Herpes In Immunocopetent And Hiv-Infected Individuals, Reduction Of Risk Of Heterosexual Transmission Of Genital Herpes |
| U-531 |
Treatment Of Patients With Essential Hypertension. May Be Used Alone Or Given With Other Classes Of Antihypertensives, Especially Thiazide Derivatives |
| U-532 |
Treatment Of Bronchospasm Associated With Copd In Patients Requiring More Than One Broncho Dilator |
| U-533 |
Erectile Dysfunction |
| U-534 |
Humalog Is An Insulin Analog That Is Indicated In The Treatment Of Patients With Diabetes Mellitus For The Control Of Hyperglycemia |
| U-535 |
Treatment Of Social Anxiety Disorder |
| U-536 |
Contrast Agent For Magnetic Resonace Imaging |
| U-537 |
Treatment Of Conditions Related To Hyperaldosteronism Such As Hypertension And Cardiac Insufficiency, With Eplerenone |
| U-538 |
First Line Treatment Of Severe Hypertension, In Patients With Hypertension Severe Enough That The Value Of Achieving Prompt Blood Pressure Control Exceeds The Risk Of Initiating Combination Therapy In These Patients |
| U-539 |
Treatment Of Moderate To Severe Dementia Of The Alzheimer's Type |
| U-54 |
Reversal Agent Or Antagonist Of Nondepolarizing Neuromuscular Blocking Agents |
| U-540 |
Treatment Of Fungal Infections |
| U-541 |
Method Of Treatment Of Adults Infected With Hiv-1 |
| U-542 |
Method Of Treating Patient With Type 2 Diabetes By Once Daily Administration |
| U-543 |
Treatment Of Schizophrenia |
| U-544 |
Treatment Of Overactive Bladder. Treatment Of Urinary Incontinence. |
| U-545 |
Method For The Prevention And/Or Treatment Of Thrombotic Episodes, Such As Myocardial Infarction, In A Human Patient And Method For The Prevention Of Venous Thrombosis In A Postoperative Human Patient |
| U-546 |
Use Of Repaglinide In Combination With Metformin To Lower Blood Glucose |
| U-547 |
Maintenance Monotherapy For Bipolar Disorder |
| U-548 |
A Method Of Reducing Flush In An Individual Being Treated For A Lipidemic Disorder And Effectively Treating The Lipidemic Disorder |
| U-549 |
Use In The Treatment Of Men With Advanced Symptomatic Prostate Cancer |
| U-55 |
Treatment Of Pain |
| U-550 |
Treatment Of Bipolar Disorder And Schizophrenia |
| U-551 |
Method For Reducing Toxicity Of Alimta Treated Patients By Administering Folic Acid |
| U-552 |
Treatment Of Hypertension And Hyperlipidemia With A Single Composition |
| U-553 |
Management Of Pain And Discomfort Associated With Peridontal Scaling And Root Planning Procedures By Application Of An Eutectic Mixture Of Local Anesthetics To Peridontal Pockets |
| U-554 |
Treating Hiv Infection With Indinavir Sulfate In Combination With Antiretroviral Agents |
| U-555 |
Treatment Of Complicated Urinary Tract Infections And Acute Uncomplicated Pyelonephritis |
| U-556 |
Use As Adjunct Diagnostic For Serum Thyroglobulin (Tg) Testing |
| U-557 |
Nasal Treatment Of Seasonal And Perennial Allergic Rhinitis Symptoms |
| U-558 |
Indicated For The Relief Of Bronchospasm In Patients 2-12 Years Of Age With Asthma (Reversible Obstructive Airway Disease) |
| U-559 |
Method Of Decreasing Or Reducing Parathyroid Hormone Level; Method Of Modulating Parathyroid Hormone Secretion;Method Of Treating Hyperparathyroidism; Method Of Reducing Serum Ionized Calcium Level |
| U-56 |
Aid To Smoking Cessation |
| U-560 |
Method Of Decreasing Parathyroid Hormone Level;Method Of Treating Hyperparathyroidism |
| U-561 |
Cosopt Is Indicated For The Reduction Of Elevated Intraocular Pressure In Patients With Open-Angle Glaucoma Or Ocular Hypertension Who Are Insufficiently Responsive To Beta Blockers |
| U-562 |
Topical Treatment Of Cutaneous Lesions In Patients With Aids-Related Kaposi's Sarcoma |
| U-563 |
Marinol Is Indicated For, Inter Alia, Anorexia Associated With Weight Loss In Patients With Aids |
| U-564 |
Treatment Of Hiv In Concomitant Therapy |
| U-565 |
Treatment Of Seasonal And Perennial Allergic Rhinitis Symptoms, And Chronic Urticaria |
| U-566 |
For The Long-Term, Once-Daily, Maintenance Treatment Of Bronchospasm Associated With Chronic Obstructive Pulmonary Disease (Copd), Including Chronic Bronchitis And Emphysema |
| U-567 |
Method Of Treating Infertility |
| U-568 |
Method Of Using Fsh Alone (Without Exogenous Lh) In In Vitro Fertilization |
| U-569 |
Method Of Using Fsh Alone (Without Exogenous Lh) In In Vitro Fertilization And Wherein Thereafter An Ovulatory Inducing Amount Of Hcg Is Administered |
| U-57 |
Ophthalmic Use Of Norfloxacin |
| U-570 |
Method Of Using Fsh Alone (Without Exogenous Lh) In In Vitro Fertilization And Wherein The Daily Amount Of Fsh Is About 5-10 Iu/Kg |
| U-571 |
Treatment Of Agitation Associated With Schizophrenia And Bipolar I Mania |
| U-572 |
Intensive Care Unit Sedation |
| U-573 |
Treatment Of Acute Promyelogenous Leukemia (Apl) |
| U-574 |
Prophylaxis And Treatment Of The Nasal Symptoms Of Seasonal Allergic Rhinitis And Treatment Of The Nasal Symptoms Of Perennial Allergic Rhinitis In Adults And Pediatric Patients 12 Years Of Age And Older |
| U-575 |
Lotemax Opthalmic Suspension Is Indicated For The Treatment Of Steroid Responsive Conditions Of The Palpebral Bulbar Conjunctiva, Cornea And Anterior Segment Of The Globe. |
| U-576 |
Alrex Opthalmic Suspension Is Indicated For The Temporary Relief Of The Signs And Symptoms Of Seasonal Allergic Conjunctivitis. |
| U-577 |
Treatment Of Benign Prostatic Hyperplasia With Finasteride In Combination With Doxazosin |
| U-578 |
Treatment Of Community Acquired Pneumonia, Acute Exacerbation Of Chronic Bronchitis, And Acute Bacterial Sinusitis Caused By Susceptible Strains Of Designated Microorganisms In Patients 18 Years And Older. |
| U-579 |
Treatment Of Epilepsy And/Or Migraine. |
| U-58 |
Method Of Treating Inflammatory Intestinal Diseases |
| U-580 |
Treatment Of Disorders Of The Serotonergic System Such As Depression And Anxiety-Related Disorders |
| U-581 |
Method Of Treating A Condition Capable Of Treatment By Inhalation, E.G. Asthma, Comprising Administration Of A Formulation Claimed In Us Patent No. 6743413 |
| U-582 |
Method For The Treatment Of A Respiratory Disorder, E.G. Asthma, Comprising Administering An Effective Amount Of An Aerosol Composition To A Patient From A Metered Dose Inhaler System As Claimed In Us Patent No. 6253762 |
| U-583 |
Method For The Treatment Of A Respiratory Disorder, E.G. Asthma, Comprising Administering To A Patient By Inhalation, A Metered Aerosol Dose Of A Drug Formulation From The Metered Dose Inhaler System Claimed In Us 6546928 |
| U-584 |
Single-Dose Administration By The Epidural Route, At The Lumbar Level, For The Treatment Of Pain Following Major Surgery |
| U-585 |
To Promote Weight Gain After Weight Loss In Certain Types Of Patients |
| U-586 |
An Intermediate Release Nicotinic Acid Formulation Suitable For Oral Administration Once-A-Day As A Single Dose For Treating Hyperlipidemia Without Causing Drug-Induced Hepatotoxicity Or Elevations In Uric Acid Or Glucose Or Both |
| U-587 |
Use Of Eplerenone In Combination With An Angiotensin Converting Enzyme (Ace) Inhibitor (And Optionally A Diuretic) For Treating Congestive Heart Failure And Hypertension |
| U-588 |
Short-Term Treatment Of Active Duodenal Ulcer; Treatment Of Heartburn And Other Symptoms Associated With Gerd; Short-Term Treatment Of Erosive Esophagitis; Maintenance Of Healing Of Erosive Esophagitis |
| U-589 |
Method For Treatment Of A Respiratory Disorder, E.G., Bronchospasm, Comprising Administering An Effective Amount Of An Aerosol Composition To A Patient From A Metered Dose Inhaler System As Claimed In U.S. Patent No. 6131966 |
| U-59 |
Method Of Treating Hypercholesterolemia |
| U-590 |
Method For Treatment Of A Respiratory Disorder,E.G.,Bronchospasm,Comprising Administering To A Patient By Oral Or Nasal Inhalation A Drug Formulation By Using The Metered Dose Inhaler System As Claimed In Us Patent No.6532955 |
| U-591 |
Treatment Of Attention Deficit Hyperactivity Disorder Using A Dosage Form Which Provides Once-Daily Oral Administration Of A Phenidate Drug |
| U-592 |
Treatment Of Primary Hypercholesterolemia, Mixed Hyperlipidemia And/Or Homozygous Familial Hypercholesterolemia (Hofh) |
| U-593 |
Treatment Of Primary Hypercholesterolemia, Mixed Hyperlipidemia And/Or Homozygous Familial Hypercholesterolemia (Hofh) |
| U-594 |
Prevention Of Postmenopausal Osteoporosis |
| U-595 |
35 Mg Orally Once A Week For Prevention Of Osteoporosis In Postmenopausal Women; 35 Mg Orally Once A Week For Treatment Of Osteoporosis In Postmenopausal Women |
| U-596 |
Treatment Of Hormone Receptor Positive Metastatic Breast Cancer In Postmenopausal Women With Disease Progression Following Antiestrogen Therapy |
| U-597 |
Forteo Is Indicated For The Treatment Of Post Menopausal Women With Osteoporosis Who Are At High Risk For Fracture |
| U-598 |
Prophylactic Treatment Of Migraine |
| U-599 |
Method For Treating Allergic Conjunctivitis |
| U-6 |
Method Of Producing Sympathomimetic Effects |
| U-60 |
Nasal Administration Of Butorphanol |
| U-600 |
A Method Of Treating A Patient In Need Of Ophthalmic Antimicrobial Therapy With Levofloxacin |
| U-601 |
Treatment Of Bipolar Disorder |
| U-602 |
Signs And Symptoms Of Osteoarthritis, Rheumatoid Arthritis In Adults, And/Or Pauciarticular Or Polyarticular Course Juvenile Rheumatoid Arthritis, Acute Pain In Adults; Primary Dysmenorrhea; And/Or Acute Migraine Attacks In Adults |
| U-603 |
Method Of Treating Infections Comprising Orally Administering An Effective Amount Of The Fda Approved Oral Suspension |
| U-604 |
Method Of Lowering Blood Glucose By Once Daily Administration |
| U-605 |
Treatment Of Major Depressive Disorder(Mdd);Although The Mehchanism Of The Antidepressant Action Of Duloxetine In Humans Is Unknown, It Is Believed To Be Related To Its Potentiation Of Seratonergic And Noradrenergic Activity In The Cns |
| U-606 |
Use Of Irinotecan In Combination With 5-Fluorouracil And Leucovorin For The Treatment Of Metastatic Colrectal Cancer |
| U-607 |
Cancidas Is Indicated For Empirical Therapy For Presumed Fungal Infections In Febrile, Neutropenic Patients. |
| U-608 |
Use Of Quinolone Compounds Against Pneumococcal Pathogenic Bacteria |
| U-609 |
Use Of Quinolone Compounds Against Quinolone-Resistant Pneumococcal Pathogenic Bacteria |
| U-61 |
Cerebral And Peripheral Arteriography And Ct Imaging Of The Head |
| U-610 |
Atrovent Hfa (Ipratropium Bromide Hfa) Inhalation Aerosol Is Indicated As A Bronchodilator For Maintenance Treatment Of Bronchospasm Associated With Chronic Obstructive Pulmonary Disease, Including Chronic Bronchitis And Emphysema. |
| U-611 |
Method Of Using Desloratadine To Treat Seasonal And Perennial Allergic Rhinitis, Pruritis, And Chronic Idiopathic Urticaria In Patients 2 Years Of Age And Older |
| U-612 |
Treatment Of Seasonal Allergy Symptoms With Nasal Congestion In Adults And Children 12 Years Of Age And Older |
| U-613 |
Reduction Of Serum Phosphate |
| U-614 |
Treatment Of Sexual Dysfunction |
| U-615 |
Adjunctive Therapy To Diet In Adults To Reduce Ldl-C, Total-C, Triglycerides And Apo B, And Increase Hdl-C In Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia (Types Iia, Iib) And To Treat Hypertriglyceridemia (Types Iv, V) |
| U-616 |
Management Of Persistent, Moderate To Severe Pain In Patients Requiring Continuous, Around-The-Clock Analgesia With A High Potency Opioid For An Extended Period Of Time Generally Weeks To Months Or Longer |
| U-617 |
Treatment Of Acute Promyelogenous Leukemia (Apl) |
| U-618 |
Use Of Rosuvastatin Calcium To Reduce Elevated Total-C, Ldl-C, Apob, Nonhdl-C Or Tg Levels; To Increase Hdl-C In Adult Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia; And To Slow The Progression Of Atherosclerosis. |
| U-619 |
Treatment Of Malignant Neoplasm |
| U-62 |
Coronary Arteriography, Left Ventriculography, Ct Imaging Of The Body, Intravenous Excretory Urography, Intravenous Digital Subtraction Angiography And Venography |
| U-620 |
Treatment Of Insomnia |
| U-621 |
Method Of Treating Cancer |
| U-622 |
Treatment Of Vegf Mediated Ocular Disease. |
| U-623 |
Short Term Treatment Of Active Benign Gastric Ulcer |
| U-624 |
Reduction Of Risk Of Upper Gastrointestinal Bleeding In Critically Ill Patients |
| U-625 |
Allergic Rhinitis Or Nasal Polyps |
| U-626 |
Clolar Is Indicated For The Treatment Of Pediatric Patients 1 To 21 Years Old With Relapsed Or Refractory Acute Lymphoblastic Leukemia After At Least Two Prior Regimens |
| U-627 |
Treatment Of Patients Using Extended-Release Carbamazepine |
| U-628 |
Use Of Avandia In Combination With A Sulfonylurea, And In Combination With Metformin And A Sulfonylurea To Improve Glycemic Control In Patients With Type 2 Diabetes Mellitus |
| U-629 |
Method Of Inducing A Hypnotic Or Sedative Effect In A Human By Administering Eszopiclone |
| U-63 |
Isoprenaline Antagonism On The Heart Rate Or Blood Pressure |
| U-630 |
Treating Urinary Incontinence By Administering An Extended-Release Form Of Darifenacin |
| U-631 |
Treating A Disease Of Altered Motility Or Tone Of Smooth Muscle By Administering A Muscarinic Receptor Antagonizing Amount Of Darifenacin |
| U-632 |
Method Of Treatment Of Cancer By Administering Particles Of Paclitaxel That Have A Protein Coating |
| U-633 |
Method For Treatment Of Tumors By Administering Paclitaxel At A Dose In The Range Of About 30mg/Meter Square To About 100mg/Meter Square In A Pharmaceutically Acceptable Formulation That Does Not Contain Cremophor |
| U-634 |
Method For Delivery Of A Biologic (Including Antineoplastic Agents) By Administering To A Patient An Effective Amount Of A Biologic As A Solid Or Liquid With A Polymeric Biocompatible Material |
| U-635 |
Treatment Of Gerd, Maintenance Of Healing Of Erosive Esophagitis And Risk Reduction Of Nsaid Associated Gastric Ulcers |
| U-636 |
Treatment Or Prevention Of Bronchospasm Or Asthmatic Symptoms |
| U-637 |
Treatment Of Diabetes With An Amylin Agonist |
| U-638 |
Treatment Of Diabetes With An Amylin Agonist, Including With Insulin |
| U-639 |
Treatment Of A Mammal Having A Need Of Or Reduced Ability To Produce Insulin With An Insulin And An Amylin Such As Pramlintide |
| U-64 |
Treatment Of Viral Infections |
| U-640 |
Use Of An Amylin Agonist To Reduce Gastric Motility And Treat Post Prandial Hypergylcemia |
| U-641 |
Use Of An Amylin Agonist Having Specified Binding Activity To Reduce Gastric Motility, Including Use Through Parenteral Administration |
| U-642 |
Treatment And Prevention Of Osteoporosis |
| U-643 |
The Short Term Treatment (Up To 10 Days) In Pts Having Gastroesophageal Reflux Disease (Gerd) As An Alternative To Oral Therapy In Pts When Therapy With Nexium Capsules Is Not Possible Or Appropriate |
| U-644 |
Treatment Of Seasonal Allergic Rhinitis |
| U-645 |
Treatment Of Asthma |
| U-646 |
Method Of Treating Otitis |
| U-647 |
Treatment Of Osteoporosis In Post Menopausal Women And/Or The Treatment To Increase Bone Mass In Men With Osteoporosis |
| U-648 |
The Treatment Of Osteoporosis In Postmenopausal Women And/Or The Treatment To Increase Bone Mass In Men |
| U-649 |
A Method For Treating A Tumor Disease |
| U-65 |
Method Of Treatment Of A Patient Infected With Hiv |
| U-650 |
Treatment Of Esophageal Candidiasis And Prophylaxis Of Candida Infections In Hsct Patients |
| U-651 |
Treatment Of Acute Promyelocytic Leukemia (Apl) |
| U-652 |
Treatment Of Cardiac Arrhythmia |
| U-653 |
Stimulating Insulin Release By Administering Exenatide |
| U-654 |
Lowering Plasma Glucagon In A Subject In Need Thereof, Including One With Type 2 Diabetes, By Administering An Exedin Or Analog, Such As Exendin-4 |
| U-655 |
Treatment Of Mild To Moderate Active Chrohn's Disease Involving The Ileum And/Or The Ascending Colon And The Maintenance Of Clinical Remission Of Mild To Moderate Crohn's Disease Involving The Ileum And/Or Ascending Colon For Up To 3 Months |
| U-656 |
Reducing Gastric Motility Or Delaying Gastric Emptying By Administering An Exendin, Such As Exendin-4 |
| U-657 |
Prevention Of Osteoporosis In Postmenopausal Women |
| U-658 |
Treatment Of Advanced Hormone-Dependent Breast Cancer |
| U-659 |
Treatment Of Locally Advanced Or Metastatic Non Small-Cell Lung Cancer (Nsclc) After Failure Of At Least One Prior Chemotherapy Regimen |
| U-66 |
Triphasic Regimen |
| U-660 |
Treatment Of Hypertension And Treatment Of Heart Failure |
| U-661 |
Treatment Of Seizure Disorder |
| U-662 |
Treatment Of Osteoporosis In Postmenopausal Women |
| U-663 |
The Treatment Of Uncomplicated Urinary Tract Infections |
| U-664 |
Treatment Of Conditions For Which An Aldosterone Receptor Blocker Is Indicated, Such As Hypertension, Heart Failure, And Post-Myocardial Infarction |
| U-665 |
Method Of Using The Drug Substance/Drug Product For Ultrasound Imaging |
| U-666 |
Method Of Treating Adhd |
| U-667 |
Management Of Incontinence; Method For Treating Incontinence |
| U-668 |
Levemir Is A Long-Acting Basal Insulin Analog That Is Indicated In The Treatment Of Patients With Diabetes Mellitus |
| U-669 |
Indication Of Type Ii Diabetes |
| U-67 |
Method Of Inducing Anesthesia In A Warm Blooded Animal |
| U-670 |
Treatment Of Hiv-1 Infection By The Co-Administration Of Tipranavir And Ritonavir. |
| U-671 |
Prevention And Treatment Of Secondary Hyperparathyroidism Associated With Chronic Kidney Disease (Ckd) Stage 3 And 4 |
| U-672 |
Treatment Of Inflammation Or An Inflammation-Associated Disorder |
| U-673 |
Method Of Treatment With Once-Daily Doses Of 625mg/5ml |
| U-674 |
Method Of Treating Insomnia Charachterized By Difficulty With Sleep Onset |
| U-675 |
Prophylaxis And Chronic Treatment Of Asthma; Relief Of Symptoms Of Allergic Rhinitis |
| U-676 |
Method Of Treating Attention Deficit Disorder Using Oral Administration Of A Bi-Modal Or Pulsatile Release Composition |
| U-677 |
A Method Of Treating Disease Amenable To Treatment With A Phenidate Drug By Once Daily Oral Administration Of An Extended Release Dosage Form |
| U-678 |
Method Of Treating Attention Deficit Disorder And/Or Attention Deficit Hyperactivity Disorder |
| U-679 |
Adjunct To Diet And Exercise To Improve Glycemic Control In Patients With Type 2 Diabetes Who Are Already Treated With A Pioglitazone And Metformin |
| U-68 |
Treatment Of Actinic Keratosis |
| U-680 |
A Method Of Treating Dyslipidemia And Dyslipoproteinemia Using A Dosage Form That Can Provide An Effective Amount Of Fenofibrate To A Patient In A Fasted State Which Is At Least 90% Of The Auc Amount Provided By The Dosage Form |
| U-681 |
Treatment Of Primary Igf-1 Deficiency |
| U-682 |
Non-Benzodiazepine Hypnotic Agent Indicated For Treatment Of Insomnia, Characterized By Difficulties With Sleep Onset And/Or Sleep Maintenance |
| U-683 |
Prevention Or Treatment Of Ischemic Heart Disease |
| U-684 |
Treatment Of Uncomplicated Skin Manifestations Of Chronic Idiopathic Urticaria In Adults And Children 6 Years Of Age And Older |
| U-685 |
Expectorant And Cough Suppressant |
| U-686 |
Expectorant And Nasal Decongestant |
| U-687 |
Reducing Food Intake In A Subject With Type 2 Diabetes By Administering An Exendin, Such As Exendin-4 |
| U-688 |
Treatment Of Hiv-Infection In Combination With Other Antiretroviral Agents |
| U-689 |
Treatment Of Patients With T-Cell Acute Lymphoblastic Leukemia Whose Disease Has Not Responded To Or Has Relapsed Following Treatment With At Least Two Chemotherapy Regimens |
| U-69 |
Treatment Of Pneumocystis Carinii Infections |
| U-690 |
To Improve Glycemic Control In Patients With Type 2 Diabetes Mellitus |
| U-691 |
Use As A Monotherapy, In Combination With A Sulfonylurea, Metformin Or Insulin Or In Combination With A Sulfonylurea Plus Metformin To Improve Glycemic Control In Patients With Type 2 Diabetes Mellitus |
| U-692 |
Use Of Valsartan To Reduce Cardiovascular Mortality In Clinically Stable Patients With Left Ventricular Failure Or Left Ventricular Dysfunction Following Myocardial Infarction |
| U-693 |
The Recommended Initial Dose Of Equetro Is 400mg/Day Given In Divided Doses, Twice Daily. The Dose Should Be Adjusted In 200mg Daily Increments To Achieve Optimal Clinical Response. |
| U-694 |
Lenalidomide Is An Analogue Of Thalidomide. Thalidomide Is A Known Human Teratogen That Causes Severe Life-Threatening Human Birth Defects. If Lenalidomide Is Taken During Pregnancy, It May Cause Birth Defects Or Death To An Unborn Baby. |
| U-695 |
Treatment Of Patients With T-Cell Acute Lymphoblastic Leukemia And T-Cell Lymphoblastic Lymphoma Whose Disease Has Not Responded To Or Has Relapsed Following Treatment With At Least Two Chemotherapy Regimens |
| U-696 |
Treatment Of Patients With T-Cell Lymphoblastic Lymphoma Whose Disease Has Not Responded To Or Has Relapsed Following Treatment With At Least Two Chemotherapy Regimens |
| U-697 |
A Method Of Using Rinfabate Recombinant (Rhigfbp-3) With Mecasermin Recombinant (Rhigf-1) To Promote Linear Growth In The Tratment Of Primary Igf-1 Deficiency |
| U-698 |
Method Of Using Antagonist Of Arginine Vasopressin (Ava) V1a And V2 Receptors For Intravenous Treatment Of Pateints With Euvolemic Hyponatremia |
| U-699 |
Nasal Treatment Of Seasonal And Perennial Allergic Rhinitis Symptoms |
| U-7 |
Increasing Cardiac Contractility |
| U-70 |
Treatment Of Transient Insomnia |
| U-700 |
Treatment And Prevention Of Osteoporosis In Postmenopausal Women |
| U-701 |
Treatment Of Hypercholesterolemia And/Or Hypertriglyceridemia |
| U-702 |
Topical Aerosol Hair Regrowth Treatment |
| U-703 |
Treatment Of Protein Kinase Related Disorders, Such As Gastrointestinal Stromal Tumor And Renal Cell Carcinoma With Sunitinib |
| U-704 |
Method Of Administering Insulin Via Inhalation |
| U-705 |
Treating Chronic Angina By Administering An Extended Release Form Of Ranolazine |
| U-706 |
Treatment Of Benign Prostatic Hyperplasia |
| U-707 |
Allergic Rhinitis |
| U-708 |
Treatment Of Chronic Non-Infectious Uveitis Affecting The Posterior Segment Of The Eye |
| U-709 |
Method Of Combating Bacteria In A Patient |
| U-71 |
Method Of Treatment Of Heart Failure |
| U-710 |
A Method Of Treating Respiratory Disorders, E.G., Asthma, Which Comprises Administration By Inhalation Of An Effective Amount Of A Pharmaceutical Formulation As Claimed In Us Patent No. 5658549 |
| U-711 |
Acute And Longer-Term Treatment Of Major Depressive Disorder |
| U-712 |
A Method Of Using A Nicotinic Acid Formulation To Reduce Elevated Tc, Ldl-C And Tg Levels, And Raise Hdl-C Levels In Patients With Hyperlipidemia |
| U-713 |
Treatment Of Mild To Moderate Dementia Of The Alzheimer's Type |
| U-714 |
Topical Treatment Of Interdigital Tinea Pedis And Tinea Corporis Due To Trichophyton Rubrum, Trichophyton Mentagrophytes Or Epidermophyton Floccosum |
| U-715 |
For Cleansing The Bowel In Preparation For Colonoscopy, In Adults 18 Years Of Age Or Older |
| U-716 |
The Treatment Or Prevention Of Bronchospasm In Adults And Children 4 Years Of Age And Older With Reversible Obstructive Airways Disease And The Prevention Of Exercised-Induced Bronchospasm In Patients 4 Years Of Age And Older |
| U-717 |
Method Of Relieving Or Preventing Constipation In A Human Constipated Patient |
| U-718 |
Treatment Of Fungal Infections |
| U-719 |
Treatent Of Psychosis |
| U-72 |
Treatment Of Migraine |
| U-720 |
Treatment Of Neuroleptic Diseases |
| U-721 |
Treatment Of Influenza |
| U-722 |
Prophylaxis Of Influenza |
| U-723 |
Prophylactic Treatment Of Migraine |
| U-724 |
Method Of Treating Seizures |
| U-725 |
Allergic Rhinitis And Urticaria |
| U-726 |
Allergic Rhinitis |
| U-727 |
For The Treatment Of Attention Deficit Hyperactivity Disorder (Adhd) |
| U-728 |
Method For Treating Bacterial Infection |
| U-729 |
Treatment Of Gastroesophageal Reflux Disease (Gerd), Risk-Reduction Of Nsaid-Associated Gastric Ulcer, H. Pylori Eradication To Reduce The Risk Of Duodenal Ulcer Recurrence |
| U-73 |
Method Of Treating Diseases Or Infections Caused By Mycetes |
| U-730 |
Use As A Nasal Spray For Treatment Of The Symptoms Of Seasonal Allergic Rhinitis And Vasomotor Rhinitis |
| U-731 |
Use In Combination With Dexamethasone Is Indicated For The Treatment Of Patients With Newly Diagnosed Multiple Myeloma |
| U-732 |
Acute Treatment Of The Cutaneous Manifestations Of Moderate To Severe Erythema Nodosum Leprosum (Enl) |
| U-733 |
Maintenance Therapy For Prevention And Supression Of The Cutaneous Manifestations Of Enl Recurrence |
| U-734 |
First Line Therapy For Type 2 Diabetes Mellitus |
| U-735 |
Method Of Treating Chronic Iron Overload |
| U-736 |
Method For Iontophoretic Transdermal Delivery Of Fentanyl Hydrochloride |
| U-737 |
Disinfection Of Patient Skin Prior To An Invasive Procedure |
| U-738 |
Indicated For The Long-Term, Twice-Daily Maintenance Treatment Of Asthma In Patients 12 Years Of Age Or Older |
| U-739 |
Method For Treating Constipation By Opening Cic Channels In A Mamalian Subject |
| U-74 |
Method Of Providing Hypnotic Effect |
| U-740 |
For The Treatment Of Patients With Primary Biliary Cirrhosis |
| U-741 |
Combination Therapy With Cisplatin For The Treatment Of Late Stage Cervical Cancer |
| U-742 |
Twice Daily Topical Treatment Of Moderate To Severe Plaque Psoriasis. |
| U-743 |
Once A Day Topical Treatment Of The Inflammatory Lesions Of Rosacea |
| U-744 |
Treatment Of Hiv Infection In Antiretroviral Treatment-Experienced Adult Patients |
| U-745 |
Treatment Or Prevention Of Emesis |
| U-746 |
Prevention Or Treatment Of Nausea Or Emesis Induced By A Cancer Chemotherapeutic Agent |
| U-747 |
Prevention Or Treatment Of Post-Operative Nausea And Vomiting |
| U-748 |
A Method For The Treatment Of A Protein Tyrosine Kinase-Associated Disorder |
| U-749 |
Method Of Contraception |
| U-75 |
Relief Of Ocular Itching Due To Seasonal Allergic Conjunctivitis |
| U-750 |
Treatment Of Hiv-1 Infection In Adults |
| U-751 |
Once Daily Dosing Of Budesonide Via Nebulizer For The Treatment Of Asthma |
| U-752 |
Sunscreen |
| U-753 |
As An Adjunct To Diet And Exercise To Improve Glycemic Control In Patients With Type 2 Diabetes |
| U-754 |
Use For The Long-Term Maintenance Treatment Of Asthma |
